Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 12, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001604191 | |
Entity Registrant Name | First Wave BioPharma, Inc. | |
Amendment Flag | true | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q/A | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-37853 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 46-4993860 | |
Entity Address, Address Line One | 777 Yamato Road, Suite 502 | |
Entity Address, City or Town | Boca Raton | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33431 | |
City Area Code | 561 | |
Local Phone Number | 589-7020 | |
Title of 12(b) Security | Common stock, par value $0.0001 per share | |
Trading Symbol | FWBI | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 12,460,848 | |
Amendment Description | First Wave BioPharma, Inc. (the “Company”) is filing this amendment (the “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Quarterly Report”) to furnish the Interactive Data files as Exhibit 101. For the convenience of the reader, this Amendment refiles in its entirety the Quarterly Report. Additionally, this filing includes updated CEO and CFO certifications filed as Exhibits 31.1, 31.2, 32.1, 32.2. No other changes have been made to the original filing. |
Consolidated Balance Sheets (Un
Consolidated Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Current Assets: | ||
Cash and cash equivalents | $ 7,210,645 | $ 6,062,141 |
Other receivables | 0 | 551,489 |
Prepaid expenses | 291,844 | 1,256,154 |
Total Current Assets | 7,502,489 | 7,869,784 |
Property, equipment, and leasehold improvements, net | 80,387 | 18,329 |
Other Assets: | ||
Patents, net | 2,483,875 | 2,879,536 |
Goodwill | 1,944,742 | 2,054,048 |
Operating lease right-of-use assets | 368,502 | 74,238 |
Deposits | 44,034 | 27,920 |
Total Other Assets | 4,841,153 | 5,035,742 |
Total Assets | 12,424,029 | 12,923,855 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 18,582,906 | 1,685,603 |
Payable related to license agreement | 0 | 13,250,000 |
Accrued dividend payable | 349,131 | 0 |
Note payable | 0 | 552,405 |
Other current liabilities | 166,291 | 57,417 |
Total Current Liabilities | 19,098,328 | 15,545,425 |
Other liabilities | 295,689 | 19,123 |
Total Liabilities | 19,394,017 | 15,564,548 |
Stockholders' Equity: | ||
Common stock - Par value $0.0001 per share; 25,000,000 shares authorized; 11,115,228 and 3,115,031 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively. | 1,112 | 312 |
Additional paid-in capital | 137,027,567 | 93,837,739 |
Accumulated deficit | (142,731,560) | (95,366,198) |
Accumulated other comprehensive loss | (1,267,107) | (1,112,546) |
Total Stockholders' Equity | (6,969,988) | (2,640,693) |
Total Liabilities and Stockholders' Equity | 12,424,029 | 12,923,855 |
Series B Preferred Stock [Member] | ||
Stockholders' Equity: | ||
Preferred stock | 0 | 0 |
Series C Preferred Stock [Member] | ||
Stockholders' Equity: | ||
Preferred stock | $ 0 | $ 0 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2021 | Feb. 28, 2021 | Feb. 23, 2021 | Jan. 05, 2021 | Dec. 31, 2020 | Jul. 16, 2020 | Dec. 31, 2019 | Dec. 20, 2019 | Feb. 24, 2019 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
Common stock, shares authorized (in shares) | 25,000,000 | 250,000,000 | 25,000,000 | 150,000,000 | 15,000,000 | 25,000,000 | |||
Common stock, shares issued (in shares) | 11,115,228 | 3,115,031 | |||||||
Common stock, shares outstanding (in shares) | 11,115,228 | 3,115,031 | |||||||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 | |||||||
Preferred stock, shares issued (in shares) | 676.05 | ||||||||
Series B Preferred Stock [Member] | |||||||||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares authorized (in shares) | 5,194.81 | 5,194.81 | 5,194.805195 | ||||||
Preferred stock, shares issued (in shares) | 676.05 | 2,773.6 | |||||||
Preferred stock, shares outstanding (in shares) | 676.05 | 2,773.6 | |||||||
Series C Preferred Stock [Member] | |||||||||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares authorized (in shares) | 57,000 | 75,000 | 57,000 | ||||||
Preferred stock, shares issued (in shares) | 0 | 0 | |||||||
Preferred stock, shares outstanding (in shares) | 0 | 334.46 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Operating expenses: | ||||
Research and development expenses | $ 24,378,318 | $ 1,795,684 | $ 32,542,143 | $ 4,438,229 |
General and administrative expenses | 6,021,160 | 1,916,250 | 15,347,764 | 4,595,860 |
Total operating expenses | 30,399,478 | 3,711,934 | 47,889,907 | 9,034,089 |
Loss from operations | (30,399,478) | (3,711,934) | (47,889,907) | (9,034,089) |
Other income (expenses): | ||||
Interest expense | (742) | (1,203,404) | (8,840) | (5,838,417) |
Gain on settlement | 0 | 211,430 | 0 | 211,430 |
Loss on debt extinguishment | 0 | (609,998) | 0 | (609,998) |
Other income | (568) | 0 | 1,032 | 0 |
Change in fair value of liability | 0 | 0 | 532,353 | 0 |
Total other income (expenses) | (1,310) | (1,601,972) | 524,545 | (6,236,985) |
Net loss | (30,400,788) | (5,313,906) | (47,365,362) | (15,271,074) |
Other comprehensive loss: | ||||
Foreign currency translation adjustment | (41,604) | 61,232 | (154,561) | 55,007 |
Total comprehensive loss | (30,442,392) | (5,252,674) | (47,519,923) | (15,216,067) |
Net loss | (30,400,788) | (5,313,906) | (47,365,362) | (15,271,074) |
Deemed dividend on preferred stock | 0 | (8,155,212) | (4,507,125) | (8,155,212) |
Deemed dividend on preferred stock exchanges | 0 | 0 | (21,008,253) | 0 |
Preferred stock dividends | (118,089) | 0 | (349,132) | 0 |
Net loss applicable to common shareholders | $ (30,518,877) | $ (13,469,118) | $ (73,229,872) | $ (23,426,286) |
Basic and diluted weighted average shares outstanding (in shares) | 9,342,357 | 2,851,883 | 7,593,545 | 2,782,823 |
Loss per share - basic and diluted (in dollars per share) | $ (3.27) | $ (4.72) | $ (9.64) | $ (8.42) |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Series C Preferred Stock and Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Series C Preferred Stock and Warrants [Member]Additional Paid-in Capital [Member] | Series C Preferred Stock and Warrants [Member] | Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Common Stock [Member] | Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Additional Paid-in Capital [Member] | Common Stock, Pre-funded Warrants, and Cash Warrants [Member] | Common Stock Offering [Member]Common Stock [Member] | Common Stock Offering [Member]Additional Paid-in Capital [Member] | Common Stock Offering [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Common Stock [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Retained Earnings [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Promissory Notes Converted into Series B Preferred Stock and Warrants [Member]Additional Paid-in Capital [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Promissory Notes Converted into Series B Preferred Stock and Warrants [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Common Stock [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Additional Paid-in Capital [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Retained Earnings [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]AOCI Attributable to Parent [Member] | Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member] | Warrants Issued in Association With Convertible Debt [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Warrants Issued in Association With Convertible Debt [Member]Common Stock [Member] | Warrants Issued in Association With Convertible Debt [Member]Additional Paid-in Capital [Member] | Warrants Issued in Association With Convertible Debt [Member]Retained Earnings [Member] | Warrants Issued in Association With Convertible Debt [Member]AOCI Attributable to Parent [Member] | Warrants Issued in Association With Convertible Debt [Member] | Conversion Feature of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion Feature of Series B Preferred Stock [Member]Common Stock [Member] | Conversion Feature of Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Conversion Feature of Series B Preferred Stock [Member]Retained Earnings [Member] | Conversion Feature of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Conversion Feature of Series B Preferred Stock [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Common Stock [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Retained Earnings [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Series B Preferred Stock to Series C Preferred Stock [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]Common Stock [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]Retained Earnings [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Series B Preferred Stock to Common Stock [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member]Common Stock [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member]Retained Earnings [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Series B Preferred Shares Into Common Stock [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Common Stock [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Retained Earnings [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]Common Stock [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]Retained Earnings [Member] | Conversion of Series C Preferred Stock to Common Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Series C Preferred Stock to Common Stock [Member] | Common Stock Issued to Settle Accounts Payable [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock Issued to Settle Accounts Payable [Member]Common Stock [Member] | Common Stock Issued to Settle Accounts Payable [Member]Additional Paid-in Capital [Member] | Common Stock Issued to Settle Accounts Payable [Member]Retained Earnings [Member] | Common Stock Issued to Settle Accounts Payable [Member]AOCI Attributable to Parent [Member] | Common Stock Issued to Settle Accounts Payable [Member] | Series B Preferred Stock Converted into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series B Preferred Stock Converted into Common Stock [Member]Common Stock [Member] | Series B Preferred Stock Converted into Common Stock [Member]Additional Paid-in Capital [Member] | Series B Preferred Stock Converted into Common Stock [Member]Retained Earnings [Member] | Series B Preferred Stock Converted into Common Stock [Member]AOCI Attributable to Parent [Member] | Series B Preferred Stock Converted into Common Stock [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Common Stock [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Retained Earnings [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member] | Dividend on Series C Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Dividend on Series C Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Dividend on Series C Preferred Stock [Member]Common Stock [Member] | Dividend on Series C Preferred Stock [Member]Additional Paid-in Capital [Member] | Dividend on Series C Preferred Stock [Member]Retained Earnings [Member] | Dividend on Series C Preferred Stock [Member]AOCI Attributable to Parent [Member] | Dividend on Series C Preferred Stock [Member] | Dividend on Series B Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Dividend on Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Dividend on Series B Preferred Stock [Member]Common Stock [Member] | Dividend on Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Dividend on Series B Preferred Stock [Member]Retained Earnings [Member] | Dividend on Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Dividend on Series B Preferred Stock [Member] | Dividends on Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Dividends on Series B Preferred Stock [Member]Common Stock [Member] | Dividends on Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Dividends on Series B Preferred Stock [Member]Retained Earnings [Member] | Dividends on Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Dividends on Series B Preferred Stock [Member] | Preferred Stock Dividend [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Preferred Stock Dividend [Member]Common Stock [Member] | Preferred Stock Dividend [Member]Additional Paid-in Capital [Member] | Preferred Stock Dividend [Member]Retained Earnings [Member] | Preferred Stock Dividend [Member]AOCI Attributable to Parent [Member] | Preferred Stock Dividend [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Common Stock [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Additional Paid-in Capital [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Retained Earnings [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member] | Conversion Feature on Convertible Debt Issuances [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion Feature on Convertible Debt Issuances [Member]Common Stock [Member] | Conversion Feature on Convertible Debt Issuances [Member]Additional Paid-in Capital [Member] | Conversion Feature on Convertible Debt Issuances [Member]Retained Earnings [Member] | Conversion Feature on Convertible Debt Issuances [Member]AOCI Attributable to Parent [Member] | Conversion Feature on Convertible Debt Issuances [Member] | Preferred Stock [Member]Series C Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 0 | 2,680,052 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2019 | $ 0 | $ 268 | $ 68,578,263 | $ (62,694,732) | $ (1,266,555) | $ 4,617,244 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs (in shares) | 2,912 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs | $ 0 | $ 0 | 14,460,155 | 0 | 0 | 14,460,155 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature of preferred stock | $ 0 | $ 0 | $ 8,155,212 | $ 0 | $ 0 | $ 8,155,212 | $ 0 | $ 0 | $ 1,838,422 | $ 0 | $ 0 | $ 1,838,422 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock | $ 0 | $ 0 | $ (8,155,212) | $ 0 | $ 0 | $ (8,155,212) | $ 0 | $ 0 | $ (1,129,742) | $ 0 | $ 0 | $ (1,129,742) | (8,155,212) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities (in shares) | (34) | 34,127 | 0 | 621 | 0 | 10,594 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities | $ 0 | $ 3 | $ (3) | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 4,786 | $ 0 | $ 0 | $ 4,786 | $ 0 | $ 1 | $ 131,136 | $ 0 | $ 0 | $ 131,137 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | $ 0 | $ 0 | $ 5,952,516 | $ 0 | $ 0 | $ 5,952,516 | $ 986,526 | $ 986,526 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 1,252,558 | $ 0 | $ 0 | $ 1,252,558 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock exchanges | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred stock | $ 0 | $ 0 | (412,829) | 0 | 0 | (412,829) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs (in shares) | 0 | 149,520 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs | $ 0 | $ 15 | 988,333 | 0 | 0 | 988,348 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants (in shares) | 0 | 13,284 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants | $ 0 | $ 1 | 109,604 | 0 | 0 | 109,605 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement with former placement agent | 0 | 0 | 85,770 | 0 | 85,770 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 0 | 0 | 396,809 | 0 | 0 | 396,809 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | 55,007 | 55,007 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ 0 | $ 0 | 0 | (15,271,074) | 0 | (15,271,074) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2020 | 2,878 | 2,888,198 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2020 | $ 0 | $ 288 | 93,242,304 | (77,965,806) | (1,211,548) | 14,065,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2020 | 0 | 2,850,285 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2020 | $ 0 | $ 285 | 73,126,945 | (72,651,900) | (1,272,780) | (797,450) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs (in shares) | 2,912 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs | $ 0 | $ 0 | 14,460,155 | 0 | 0 | 14,460,155 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature of preferred stock | 0 | 0 | 8,155,212 | 0 | 0 | 8,155,212 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock | $ 0 | $ 0 | $ (8,155,212) | $ 0 | $ 0 | $ (8,155,212) | $ 0 | $ 0 | $ (1,129,742) | $ 0 | $ 0 | $ (1,129,742) | (8,155,212) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities (in shares) | (34) | 34,127 | 0 | 621 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities | $ 0 | $ 3 | $ (3) | $ 0 | $ 0 | $ 0 | $ 0 | $ 4,786 | $ 0 | $ 0 | $ 4,786 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | 0 | 0 | 5,952,516 | 0 | 0 | 5,952,516 | $ 0 | $ 0 | $ 986,526 | $ 0 | $ 0 | $ 986,526 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock exchanges | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred stock | $ 0 | $ 0 | (412,829) | 0 | 0 | (412,829) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants (in shares) | 0 | 3,165 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants | $ 0 | $ 0 | 22,500 | 0 | 0 | 22,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement with former placement agent | 0 | 0 | 85,770 | 0 | 85,770 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 0 | 0 | 145,680 | 0 | 0 | 145,680 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | 61,232 | 61,232 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ 0 | $ 0 | 0 | (5,313,906) | 0 | (5,313,906) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2020 | 2,878 | 2,888,198 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2020 | $ 0 | $ 288 | 93,242,304 | (77,965,806) | (1,211,548) | 14,065,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2020 | 0 | 2,774 | 3,115,031 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2020 | $ 0 | $ 0 | $ 312 | 93,837,739 | (95,366,198) | (1,112,546) | (2,640,693) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs (in shares) | 10,667 | 1,625,454 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs | $ 1 | $ 7,105,167 | $ 7,105,168 | $ 163 | $ 14,155,887 | $ 14,156,050 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock for license acquired (in shares) | 3,290 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock for license acquired | $ 1 | $ 0 | $ 0 | 2,467,648 | 0 | 0 | 2,467,649 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature of preferred stock | 0 | 0 | 0 | 4,507,125 | 0 | 0 | 4,507,125 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock | $ 0 | $ 0 | $ 0 | $ (4,507,125) | $ 0 | $ 0 | $ (4,507,125) | (4,507,125) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities (in shares) | 19,140 | (1,839) | 0 | 0 | (259) | 258,278 | (33,097) | 0 | 3,125,460 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock upon conversion of securities | $ 1 | $ 0 | $ 0 | $ (1,431) | $ 0 | $ 0 | $ (1,430) | $ 0 | $ 0 | $ 26 | $ (26) | $ 0 | $ 0 | $ 0 | $ (3) | $ 0 | $ 312 | $ (309) | $ 0 | $ 0 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued | $ 0 | $ 0 | $ 0 | $ 21,009,683 | $ 0 | $ 0 | $ 21,009,683 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock exchanges | $ (21,000,000) | $ 0 | $ 0 | $ 0 | $ (21,008,253) | $ 0 | $ 0 | $ (21,008,253) | (21,008,253) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred stock | $ 0 | $ 0 | $ 0 | (349,132) | 0 | 0 | (349,132) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares) | 0 | 0 | (1,706) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs (in shares) | 0 | 0 | 1,651,225 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs | $ 0 | $ 0 | $ 165 | 8,325,030 | 0 | 0 | 8,325,195 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued for intellectual property acquired, net (in shares) | 0 | 0 | 624,025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued for intellectual property acquired, net | $ 0 | $ 0 | $ 62 | 3,999,938 | 0 | 0 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares) | 0 | 0 | (332,913) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. | $ 0 | $ 0 | $ (33) | 33 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued upon exercise of warrants (in shares) | 0 | 0 | 945,644 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued upon exercise of warrants | $ 0 | $ 0 | $ 94 | 4,906,536 | 0 | 0 | 4,906,630 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants (in shares) | 0 | 0 | 97,230 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants | $ 0 | $ 0 | $ 10 | 1,215,849 | 0 | 0 | $ 1,215,859 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement with former placement agent (in shares) | 0 | 0 | 7,500 | 7,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement with former placement agent | $ 0 | $ 0 | $ 1 | 94,498 | 0 | 0 | $ 94,499 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 0 | 0 | 0 | 1,268,710 | 0 | 0 | 1,268,710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | 0 | (154,561) | (154,561) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ 0 | $ 0 | $ 0 | 0 | (47,365,362) | 0 | (47,365,362) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2021 | 0 | 676 | 11,115,228 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2021 | $ 0 | $ 0 | $ 1,112 | 137,027,567 | (142,731,560) | (1,267,107) | (6,969,988) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2021 | 0 | 676 | 8,258,507 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2021 | $ 0 | $ 0 | $ 826 | 120,592,372 | (112,330,770) | (1,225,503) | 7,036,924 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs (in shares) | 1,045,454 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of stock and warrants for cash, net of offering costs | $ 105 | $ 5,096,655 | $ 5,096,760 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on preferred stock exchanges | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred stock | $ 0 | $ 0 | $ 0 | (118,089) | 0 | 0 | (118,089) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares) | 0 | 0 | (1,706) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs (in shares) | 0 | 0 | 1,501,661 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock at-the-market for cash, net of offering costs | $ 0 | $ 0 | $ 150 | 7,150,697 | 0 | 0 | 7,150,847 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued for intellectual property acquired, net (in shares) | 0 | 0 | 624,025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued for intellectual property acquired, net | $ 0 | $ 0 | $ 62 | 3,999,938 | 0 | 0 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares) | 0 | 0 | (332,913) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. | $ 0 | $ 0 | $ (33) | 33 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants (in shares) | 0 | 0 | 20,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock and warrants issued to consultants | $ 0 | $ 0 | $ 2 | 123,547 | 0 | 0 | 123,549 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 0 | 0 | 0 | 182,414 | 0 | 0 | 182,414 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | 0 | (41,604) | (41,604) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ 0 | $ 0 | $ 0 | 0 | (30,400,788) | 0 | (30,400,788) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2021 | 0 | 676 | 11,115,228 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2021 | $ 0 | $ 0 | $ 1,112 | $ 137,027,567 | $ (142,731,560) | $ (1,267,107) | $ (6,969,988) |
Consolidated Statements of Ch_2
Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) | Sep. 13, 2021 | Sep. 30, 2021 | Sep. 30, 2021 |
Reverse Stock Split [Member] | |||
Stock split, conversion ratio | 10 | 10 | |
Stock split, conversion ratio | 10 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (47,365,362) | $ (15,271,074) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 9,390 | 26,556 |
Amortization | 395,661 | 395,661 |
Non-cash lease expense | (4,855) | (4,855) |
Common stock issued to settle accounts payable | 0 | 131,137 |
Change in fair value of liability | (532,353) | 0 |
Stock-based compensation | 1,268,710 | 369,517 |
Restricted stock granted to employees/directors | 0 | 27,292 |
Common stock granted to consultants | 1,310,358 | 109,605 |
Accreted interest on convertible debt | 0 | 234,334 |
Accretion of debt discount | 0 | 4,580,167 |
Loss on debt extinguishment | 0 | 609,998 |
Gain on settlement | 0 | (211,430) |
Beneficial conversion feature related to promissory note exchange | 0 | 798,413 |
Changes in assets and liabilities: | ||
Accounts receivables | 0 | (220,094) |
Other receivables | 551,489 | 2,121,336 |
Prepaid expenses | 964,310 | 446,766 |
Right of use assets | (289,409) | 0 |
Deposits | (16,114) | (4,180) |
Accounts payable and accrued expenses | 16,897,303 | 90,147 |
Accrued dividends payable | 0 | 408,043 |
Other liabilities | 385,440 | 31,104 |
Net cash used in operating activities | (26,425,432) | (5,331,557) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (71,448) | (2,808) |
Payment made related to license agreement | (10,250,000) | 0 |
Net cash used in investing activities | (10,321,448) | (2,808) |
Cash flows from financing activities: | ||
Proceeds from issuance of notes payable, net | 0 | 179,408 |
Proceeds from issuance of preferred stock, net | 7,105,168 | 13,197,740 |
Proceeds from issuance of common stock, net | 18,156,050 | 988,348 |
Proceeds from exercise of warrants | 4,906,630 | 0 |
Proceeds from issuance of convertible debt, net | 0 | 3,227,002 |
Issuance of common stock at-the-market for cash, net of offering costs | 8,325,195 | 0 |
Repayments of convertible debt | 0 | (475,000) |
Repayments of note payable | (552,405) | (623,772) |
Net cash provided by financing activities | 37,940,638 | 16,493,726 |
Increase in cash | 1,193,758 | 11,159,361 |
Effect of exchange rate changes on cash | (45,254) | 33,523 |
Cash, beginning balance | 6,062,141 | 175,796 |
Cash, ending balance | 7,210,645 | 11,368,680 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 0 | 105,460 |
Cash paid for income taxes | 0 | 0 |
Non-cash investing and financing activities: | ||
Deemed dividend on preferred stock issuances | (4,507,125) | (8,155,212) |
Deemed dividend on preferred stock exchanges | (21,008,253) | 0 |
Accrued dividends on preferred stock | (349,132) | (408,043) |
Issuance of preferred stock to settle liability related to license agreement | 2,467,649 | 0 |
Exchange of promissory notes into preferred stock and warrants | $ 0 | $ (609,998) |
Note 1 - The Company and Basis
Note 1 - The Company and Basis of Presentation | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | Note 1 The Company AzurRx BioPharma, Inc. (“ AzurRx First Wave Parent September 21, 2021, FWB Company 33749P101 September 22, 2021. On September 13, 2021, Also, on September 13, 2021, ten one 1 1 The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (“ GI The Company is currently focused on developing its pipeline of gut-restricted GI clinical drug candidates, including niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase (formerly MS1819 The Company’s niclosamide programs leverage proprietary oral and topical formulations to address multiple GI conditions, including inflammatory bowel diseases (“IBD”) indications and viral diseases. The Company is currently advancing two 2 2 19” April 2021, 2 19 September 2021, 2 October 2021 first Additionally, the Company plans to clinically advance FW-ICI-AC for Immune Checkpoint Inhibitor-associated colitis (“ ICI-AC 2022, IND September 2021. two UC CD The Company’s adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“ EPI CF CP March 2021, 2b 2 2021, 2 The Company is developing its drug candidates for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. The Company’s mission is to help protect the health and restore quality of life for the millions of people afflicted by these GI diseases. Since its inception, the Company has devoted substantially all its efforts to research and development, business development, and raising capital, and has primarily financed its operations through issuance of common stock, convertible preferred stock, convertible debt, and other debt/equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID- 19 19 In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID- 19 may The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2020, not may not 10 December 31, 2020, March 31, 2021. Going Concern Uncertainty The accompanying unaudited interim consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On September 30, 2021, November 15, 2021, January 2022 August 2022 September 2022 July 2023 19 Without adequate working capital, the Company may not not |
Note 2 - Significant Accounting
Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Note 2 Use of Estimates The accompanying unaudited consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets, and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three September 30, 2021, December 31, 2020, Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may September 30, 2021, December 31, 2020, one not The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method. Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018 07, Fair Value Measurements The Company follows Accounting Standards Codification ( ASC 820 10, ( ASC 820 As a basis for considering such assumptions, a three Level 1: Level 2: Level 3: no In certain cases, the inputs used to measure fair value may The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may not September 30, 2021. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, ( ASC 360 may not not September 30, 2021. Income Taxes Income taxes are recorded in accordance with ASC 740, ( ASC 740 not not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not September 30, 2021 December 31, 2020, not three Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU not may 15 License Agreements As more fully discussed in Note 14, FWB License Agreement 19 19 no no September 13, 2021, Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third third CMC MS1819 Research and Development Intellectual Property Acquired The Company concluded that its acquisition of FWB completed on September 13, 2021 805, not The former FWB stockholders are also entitled to (i) up to $207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. The potential milestone payments and revenue share are not September 30, 2021. may Stock-Based Compensation The Company’s board of directors (the “ Board 2014 2014 May 12, 2014, 2020 September 11, 2020 ( 2020 2020 no 2014 718, ASC 718 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Recent Accounting Pronouncements In August 2020, 2020 06 SEC December 15, 2023. |
Note 3 - Fair Value Disclosures
Note 3 - Fair Value Disclosures | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | Note 3 Fair Value Disclosures Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value September 30, 2021: Cash and cash equivalents $ 7,210,645 $ 6,709,028 $ 501,617 $ - $ 7,210,645 December 31, 2020: Cash and cash equivalents $ 6,062,141 $ 3,000,184 $ 3,061,957 $ - $ 6,062,141 Other receivables $ 551,489 $ - $ - $ 551,489 $ 551,489 Note payable $ 552,405 $ - $ - $ 552,405 $ 552,405 On September 30, 2021, December 31, 2020, 1 The fair value of other receivables approximates carrying value as these consist primarily of French research and development tax credits that are normally received the following year. The fair value of the note payable in connection with the financing of directors and officer’s liability insurance approximates carrying value due to the terms of such instruments and applicable interest rates. |
Note 4 - Asset Acquisition
Note 4 - Asset Acquisition | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Asset Acquisition [Text Block] | Note 4 Asset Acquisition The Asset Acquisition On September 13, 2021, September 13, 2021 ( FWB Merger Agreement Merger Sub September 13, 2021, FWB Merger At the effective time of the FWB Merger, the former FWB stockholders received an applicable pro rata share of (i) $3.0 million in cash and (ii) 624,025 shares of the Common Stock. The remaining non-contingent purchase price is payable to the former FWB stockholders on a pro rata basis upon the Company’s payment of (i) $8.0 million in cash, payable within 45 March 31, 2022. November 15, 2021, $500,000 January 2022 August 2022 $1.0 September 2022 July 2023 19 no The former FWB stockholders are also entitled to up to $207 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals relating to the use of the acquired assets. All milestone payments will be payable in cash, provided that 25% of the milestone payments attributable to a certain IBD indications may third Accounting Treatment The Company concluded that the FWB Merger should be accounted for as an asset acquisition under ASC 805 not not The potential milestone payments and revenue share are not September 30, 2021. may |
Note 5 - Property, Equipment an
Note 5 - Property, Equipment and Leasehold Improvements | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 5 Property, equipment, and leasehold improvements consisted of the following: September 30, December 31, 2021 2020 Laboratory equipment $ - $ 2,410 Computer equipment and software 11,540 19,676 Office equipment 48,277 5,483 Leasehold improvements 28,000 29,163 Total property, plant, and equipment 87,817 56,732 Less accumulated depreciation (7,430 ) (38,403 ) Property, plant and equipment, net $ 80,387 $ 18,329 Depreciation expense for the three September 30, 2021 2020 nine September 30, 2021 2020 $9,000 $27,000, During the nine September 30, 2021, |
Note 6 - Intangible Assets and
Note 6 - Intangible Assets and Goodwill | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 6 Patents Pursuant to the Mayoly asset purchase agreement entered in March 2019 ( 14 MS1819 Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 449,280 Due to Mayoly at December 31, 2020 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745 Patents are as follows: September 30, December 31, 2021 2020 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (1,318,870 ) (923,209 ) Patents, net $ 2,483,875 $ 2,879,536 Amortization expense was approximately $132,000 and $132,000 for the three September 30, 2021, 2020, Amortization expense was approximately $396,000 and $396,000 for the nine September 30, 2021, 2020, As of September 30, 2021, five 2021 2026 2021 (balance of year) $ 131,887 2022 527,548 2023 527,548 2024 527,548 2025 527,548 2026 241,796 Total $ 2,483,875 Goodwill is as follows: Goodwill Balance on January 1, 2020 $ 1,886,686 Foreign currency translation 167,362 Balance on December 31, 2020 2,054,048 Foreign currency translation (109,306 ) Balance on September 30, 2021 $ 1,944,742 |
Note 7 - Accounts Payable and A
Note 7 - Accounts Payable and Accrued Expenses | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 7 Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2021 2020 Trade payables $ 18,447,834 $ 1,558,591 Accrued expenses 135,072 127,012 Total accounts payable and accrued expenses $ 18,582,906 $ 1,685,603 The increase in trade payables as of September 30, 2021 December 31, 2020 |
Note 8 - Note Payable
Note 8 - Note Payable | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 8 Directors and Officer s Liability Insurance On November 30, 2020, September 30, 2021 December 31, 2020, |
Note 9 - Convertible Debt
Note 9 - Convertible Debt | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Convertible Debt Disclosure [Text Block] | Note 9 The ADEC Note Offering On February 14, 2019, ADEC two ADEC Note, ADEC Notes ADEC Note Offering In December 2019, January 2020, ADEC Notes Senior Convertible Promissory Note Offering On December 20, 2019, Promissory Note Promissory Notes Note Investors Note Warrants Promissory Promissory Note Offering The Promissory Notes were scheduled to mature on September 20, 2020, Promissory Note Conversion Shares Conversion Option Prepayment Option On January 2, 2020, January 3, 2020, January 9, 2020, As additional consideration for the execution of the Promissory NPA, each Note Investor also received Note Warrants to purchase that number of shares of Common Stock equal to one Note Warrant Shares five July 2020, 11, September 2020. In connection with the three January 2020 Placement Agent Warrants five The Company determined the Prepayment Option feature represents a contingent call option. The Company evaluated the Prepayment Option in accordance with ASC 815 15 25. not 815 15 25. 815 not The Company evaluated the Promissory Notes for a beneficial conversion feature in accordance with ASC 470 20. Pursuant to the January 2020 first On June 1, 2020, December 20, 2019, Note Amendment 470 50 not no During the three September 30, 2020, During the nine September 30, 2020, |
Note 10 - Other Liabilities
Note 10 - Other Liabilities | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Other Liabilities Disclosure [Text Block] | Note 10 Other liabilities consisted of the following: September 30, December 31, 2021 2020 Current Lease liabilities $ 94,794 $ 57,417 Other liabilities 71,497 - $ 166,291 $ 57,417 Long-term Lease liabilities $ 295,689 $ 19,123 $ 295,689 $ 19,123 |
Note 11 - Equity
Note 11 - Equity | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 11 Equity The Company’s certificate of incorporation, as amended and restated (the “ Charter On February 24, 2021 2021 one 1:5 one 1:10 one 2021 Reverse Split September 13, 2021, ten one 1 Common Stock The Company had 11,115,228 and 3,115,031 shares of its Common Stock issued and outstanding on September 30, 2021 December 31, 2020, Each holder of Common Stock is entitled to one Bylaws not In addition, the holders of Common Stock will be entitled to receive ratably such dividends, if any, as may Holders of Common Stock have no no may may Preferred Stock The Company has 10,000,000 shares of preferred stock, par value $0.0001 per share, authorized and available for issuance in one may no may On July 16, 2020, may not may September 30, 2021, On January 5, 2021, not September 30, 2021, On September 30, 2021, Series B Convertible Preferred Stock Pursuant to the Certificate of Designation of Rights and Preferences of the Series B Preferred Stock (the “ Series B Certificate of Designation Ranking The Series B Preferred Stock will rank senior to the Common Stock with respect to distributions of assets upon the liquidation, dissolution or winding up of the Company. Stated Value Each share of Series B Preferred Stock has a stated value of $7,700, subject to adjustment for stock splits, combinations, and similar events (the “ Series B Stated Value Dividends Each holder of shares of Series B Preferred Stock, in preference and priority to the holders of all other classes or series of stock of the Company, is entitled to receive dividends, commencing from the date of issuance. Such dividends may June December December 31, 2020, not not may September 30, 2021, Liquidation Preference; Liquidation Rights Under the Certificate of Designations, each share of Series B Preferred Stock carries a liquidation preference equal to the Series B Stated Value (as adjusted thereunder) plus accrued and unpaid dividends thereon (the “ Liquidation Preference If the Company voluntarily or involuntarily liquidates, dissolves or winds up its affairs, each holder of the Series B Preferred Stock will be entitled to receive out of the Company’s assets available for distribution to stockholders, after satisfaction of liabilities to creditors, if any, but before any distribution of assets is made on the Common Stock or any of the Company’s shares of stock ranking junior as to such a distribution to the Series B Preferred Stock, a liquidating distribution in the amount of the Stated Value of all such holder’s Series B Preferred Stock plus all accrued and unpaid dividends thereon. On September 30, 2021, Conversion Each share of Series B Preferred Stock will be convertible at the holder’s option at any time, into Common Stock at a conversion rate equal to the quotient of (i) the Series B Stated Value divided by (ii) the initial conversion price of $7.70, subject to specified adjustments for stock splits, cash or stock dividends, reorganizations, reclassifications other similar events as set forth in the Series B Certificate of Designations. In addition, at any time after the six Automatic Conversion may not Most Favored Nations (MFN) Exchange Right In the event the Company effects any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, or a combination of units thereof (a “ Subsequent Financing Series B Exchange Amount Series B Exchange Right Voting The holders of the Series B Preferred Stock, voting as a separate class, have customary consent rights with respect to certain corporate actions of the Company. The Company may not first 2014 The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 2014 May 12, 2014. 2020 September 11, 2020, 2014 The Company issued an aggregate of 79,500 stock options, during the nine September 30, 2020, 2014 13 As of September 30, 2021, 2014 RSUs 2020 The Company’s Board and stockholders adopted and approved the 2020 2020 September 11, 2020. 2020 January 1 ten December 31 not 2014 2020 ISOs 2020 The Company issued an aggregate of 175,246 stock options during the nine September 30, 2021, 2020 13 As of September 30, 2021, 2020 Equity Line with Lincoln Park In November 2019, Equity Line Agreement Lincoln Park Registration Rights Agreement Equity Line Commitment Shares no The remaining shares of Common Stock that may may 30 December 31, 2019 January 14, 2020. There is approximately $14.0 million of availability left for issuance pursuant to the Equity Line Agreement. The Company issued an aggregate of 0, and 149,519 shares of Common Stock, during the nine September 30, 2021 2020, At The Market Agreement with H.C. Wainwright On May 26, 2021, Wainwright may may 415 4 1933, May 26, 2021, three September 30, 2021, nine September 30, 2021, Common Stock Issuances 2021 During the three September 30, 2021, During the three September 30, 2021, July 2021 During the three September 30, 2021, 4 During the three September 30, 2021, 1 September 13, 2021. During the nine September 30, 2021, During the nine September 30, 2021, $94,000 During the nine September 30, 2021, During the nine September 30, 2021, 12 During the nine September 30, 2021, During the nine September 30, 2021, March 2021 July 2021 2020 During the three September 30, 2020, not During the three September 30, 2020, 34.127448 During the three September 30, 2020, During the nine September 30, 2020, $112,000 During the nine September 30, 2020, Restricted Stock and Restricted Stock Units Restricted stock refers to shares of Common Stock subject to vesting based on certain service, performance, and market conditions. Restricted stock unit awards refer to an award under the 2014 2020 During the three nine September 30, 2021, During the three September 30, 2020, During the nine September 30, 2020, During the three nine September 30, 2020, As of September 30, 2021, first MS1819 20 not September 30, 2021. As of September 30, 2020, first MS1819 20 not September 30, 2020. The Series B Private Placement and the Exchange On July 16, 2020 ( Series B Closing Date Series B Private Placement Series B Purchase Agreement Series B Investors Series B Preferred Stock Series B Warrants In connection with the Series B Private Placement, an aggregate of approximately 1,975.58 shares of Series B Preferred Stock initially convertible into 1,975,574 shares of Common Stock and related 987,783 Series B Warrants were issued for cash consideration, resulting in aggregate gross proceeds of approximately $15.2 million and aggregate net proceeds to the Company of approximately $13.2 million after deducting placement agent compensation and offering expenses. An aggregate of approximately 937.00 shares of Series B Preferred Stock initially convertible into 937,000 shares of Common Stock and related Series B Warrants to purchase 468,499 shares of Common Stock were issued to certain Series B Investors (the “ Exchange Investors Promissory Notes December 20, 2019 January 9, 2020 ( Exchange Exchange Addendum Exchange Warrants Pursuant to the Series B Private Placement and the Series B Purchase Agreement, for purposes of complying with Nasdaq Listing Rule 5635 5635 not 60 2020 2020 not 9 0th September 11, 2020, 2020 The Company prepaid the remaining outstanding balance of $25,000 aggregate principal amount of Promissory Notes, together with accrued and unpaid interest thereon through the prepayment date of approximately $1,000, held by those holders who did not January 2021 On December 31, 2020, Series C Purchase Agreement January 2021 Registered Direct Offering Concurrently with the Registered Direct Offering, in a private placement offering pursuant to the Series C Purchase Agreement (the “ January 2021 Private Placement, January 2021 January 2021 January 2021 January 2021 July 6, 2026. In connection with the January 2021 December 31, 2020, 1 No. 333 252087 January 2021 January 2021 January 21, 2021. On January 6, 2021, January 2021 January 2021 The Company paid the placement agent a cash fee equal to 8.0% and a management fee equal to 1.0% of the aggregate gross proceeds received by the Company in the January 2021 January 2021 January 2021 January 2021 January 2021 Pursuant to the January 2021 not March 31, 2021 2021 January 2021 January 2021 On February 24, 2021, 2021 Accounting for the January 2021 Upon receiving the 2021 February 24, 2021, no not no 1 may 2 Because the Series C Preferred Stock contains certain embedded features that could affect the ultimate settlement of the Series C Preferred Stock, the Company analyzed the instrument for embedded derivatives that require bifurcation. The Company’s analysis began with determining whether the Series C Preferred Stock is more akin to equity or debt. The Company evaluated the following criteria/features in this determination: redemption, voting rights, collateral requirements, covenant provisions, creditor and liquidation rights, dividends, and conversion rights. The Company determined that the Series C Preferred Stock was more akin to equity than to debt when evaluating the economic characteristics and risks of the entire Series C Preferred Stock, including the embedded features. The Company then evaluated the embedded features to determine whether their economic characteristics and risks were clearly and closely related to the economic characteristics and risks of the Series C Preferred Stock. Since the Series C Preferred Stock was determined to be more akin to equity than debt, and the underlying that causes the value of the embedded features to fluctuate would be the value of the Company’s common stock, the embedded features were considered clearly and closely related to the Series C Preferred Stock. As a result, the embedded features would not The Company concluded the freestanding January 2021 not The proceeds from the January 2021 January 2021 January 2021 Series B Most Favored Nations (MFN) Exchanges into the January 2021 Subject to the consummating the January 2021 January 2021 During the nine September 30, 2021, January 2021 February 24, 2021, 2021 February 24, 2021, As a result, as of September 30, 2021, may January 2021 January 2021 no January 2021 Accounting for the Series B Exchanges into the January 2021 During the nine September 30, 2021, February 24, 2021. nine September 30, 2021, January 2021 March 2021 On March 7, 2021, March 2021 March 2021 March 2021 Pre-Funded Warrants no March 2021 Warrants five March 2021 On March 10, 2021, March 2021 March 2021 March 2021 The Company paid the placement agent a cash fee equal to 8.0% of the aggregate gross proceeds received by the Company, or approximately $800,000. The Company also agreed to issue the placement agent or its designees warrants (the “ March 2021 March 2021 March 2021 March 2021 The March 2021 3 No. 333 231954 June 21, 2019, June 25, 2019. March 2021 The Company concluded the freestanding March 2021 March 2021 not July 2021 On July 22, 2021, July 27, 2021, 30 July 27, 2021. The Company received net proceeds from the offering of approximately $5.1 million. The Company intends to use the net proceeds from the offering for milestone payments due under the Company’s license agreements and for other general corporate purposes. The Company paid Wainwright an underwriting discount equal to 8.0% of the gross proceeds of the offering, and reimbursed Wainwright for a non-accountable expense allowance of $35,000, $125,000 in legal fees and $15,950 for clearing expenses. Additionally, as partial compensation for Wainwright’s services as underwriter in the offering, the Company issued to Wainwright (or its designees) warrants to purchase 73,181 shares of Common Stock equal to 7.0% of the aggregate number of shares of Common Stock sold in the offering (the “ Wainwright Warrants five 5 not The Company concluded the freestanding Wainwright Warrants did not Most Favored Nations (MFN) Exchange Right Under the Series B Certificate of Designations, each holder of the Series B Preferred Stock may 3 9 144 As of September 30, 2021, 1,839.76 $14.4 1,914,024 January 2021 1,914,014 As a result, as of September 30, 2021, 676.05 $349,000 may 7,406 740,612 January 2021 740,612 January 2021 1,633,720 May 26, 2021 ( ATM Agreement no |
Note 12 - Warrants
Note 12 - Warrants | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Warrants Disclosure [Text Block] | Note 12 Warrants During the three September 30, 2021, July 2021 July 2021 11. July 2021 July 22, 2021, five no 11 During the nine September 30, 2021, January 2021 11. January 2021 April 1, 2021 June 9, 2021, July 6, 2026. During the nine September 30, 2021, January 2021 January 2021 11. January 2021 January 6, 2021, July 6, 2026. January 2021 February 24, 2021. 11 During the nine September 30, 2021, January 2021 11. January 6, 2021, not 11 During the nine September 30, 2021, January 2021 January 2021 11. January 2021 January 6, 2021, July 6, 2026. no 11 During the nine September 30, 2021, January 2021 11. January 2021 January 13, 2021 June 9, 2021, July 6, 2026. February 24, 2021. During the nine September 30, 2021, March 2021 March 2021 11. March 2021 March 10, 2021, five 11 During the nine September 30, 2021, March 2021 11. March 10, 2021, not 11 During the nine September 30, 2021, March 2021 March 2021 11. March 2021 March 10, 2021, five no 11 During the nine September 30, 2021, February 8, 2021, four During the three September 30, 2021, During the nine September 30, 2021, During the nine September 30, 2021, January 2021 March 2021, During the nine September 30, 2020, January 2020 9. January 2, 2020 January 9, 2020, six 6 five During the nine September 30, 2020, January 2020 January 2, 2020 January 9, 2020, five For the three nine September 30, 2020, 11. July 16, 2020, six 6 five 11 For the three nine September 30, 2020, 11 11. July 16, 2020, six 6 five 9 For the three nine September 30, 2020, July 11. July July 16, 2020, six 6 five July 11 For the three nine September 30, 2020, July 14, 2020 five may six During the nine September 30, 2020, Warrant transactions for the nine September 30, 2021 2020 Exercise Weighted Price Per Average Warrants Share Price Warrants outstanding and exercisable on January 1, 2020 537,828 $10.70 - 73.70 $ 25.30 Granted during the period 1,988,165 $8.50 - 14.20 $ 8.80 Expired during the period (5,977 ) $32.50 - 73.70 $ 51.50 Exercised during the period - - - Warrants outstanding and exercisable on September 30, 2020 2,520,016 $8.50 - 73.70 $ 12.20 Warrants outstanding and exercisable on January 1, 2021 2,517,722 $8.50 - 73.70 $ 12.20 Granted during the period 3,995,602 $0.01 - 16.90 $ 7.77 Expired during the period (51,061 ) - - Exercised during the period (952,588 ) - - Warrants outstanding and exercisable on September 30, 2021 5,509,675 $6.87 - 66.00 $ 9.96 Warrants exercisable on September 30, 2021, Exercise Price Number of Shares Under Warrants Weighted Average Remaining Contract Life in Years Weighted Average Exercise Price $ 0.00 - 9.99 4,482,860 4.40 $ 10.00 - 19.99 840,745 3.62 $ 20.00 - 29.99 32,003 1.82 $ 30.00 - 39.99 61,155 0.61 $ 40.00 - 49.99 16,425 0.53 $ 50.00 - 59.99 72,714 0.47 $ 60.00 - 69.99 3,773 0.17 Totals 5,509,675 4.16 $ 9.96 The weighted average fair value of warrants granted during the nine September 30, 2021, 2020, September 30, 2021 Expected life (in years) 5.19 Volatility 83.8 - 90.8 % Risk-free interest rate 0.28 - 1.67 Dividend yield -% |
Note 13 - Stock Options
Note 13 - Stock Options | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Shareholders' Equity and Share-based Payments [Text Block] | Note 13 Under the 2014 2020 No not not, not On June 30, 2021, 2014 Prior Awards New Awards 2020 July 27, 2020, August 11, 2020, 2020 The terms of the New Awards to Mr. Sapirstein (the “ New Sapirstein Awards 18 first February 16, 2022, ( not 718 no no The terms of the New Awards to Mr. Schneiderman (the “ New Schneiderman Awards 2 1 19 not 718 no no During the three September 30, 2021, 2020 ten three During the three September 30, 2021, 2014 During the nine September 30, 2021, 2020 ten three During the nine September 30, 2021, 2014 During the nine September 30, 2021, During the nine September 30, 2021, 2 2 2 2 2 1 MS1819 19 During the three September 30, 2020, ten During the three September 30, 2020, January 2, 2020, 2014 2014 162 January 2, 2020, three 36 January 2, 2020. 718. January 1, 2023. During the nine September 30, 2020, ten three During the nine September 30, 2020, ten During the nine September 30, 2020, During the three September 30, 2020, During the nine September 30, 2020, During the nine September 30, 2020, 2 The fair values were estimated on the grant dates using the Black-Scholes option-pricing model with the following weighted-average assumptions: September 30, 2021 Contractual term (in years) 10 Volatility 83.8 - 90.6 % Risk-free interest rate 83.9 - 1.69 Dividend yield - % The expected term of the options is based on expected future employee exercise behavior. Volatility is based on the historical volatility of the Company’s Common Stock if available or of several public entities that are similar to the Company. The Company bases volatility this way because it may not not not During the nine September 30, 2021 2020, 2014 2020 Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2020 167,750 $ 21.70 5.37 $ - Granted during the period 287,001 $ 8.90 9.79 - Canceled during the period (23,500 ) $ 19.40 3.28 - Stock options outstanding on September 30, 2020 431,251 $ 13.80 6.52 $ - Exercisable on September 30, 2020 131,275 $ 22.20 6.09 $ - Non-vested stock options outstanding on January 1, 2020 88,350 $ 13.30 6.26 $ - Granted during the period 287,001 $ 10.00 10.00 - Vested during the period (59,375 ) $ 25.90 6.88 - Canceled during the period (16,000 ) $ 13.00 7.10 - Non-vested stock options outstanding on September 30, 2020 299,976 $ 9.80 8.75 $ - Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2021 407,026 12.46 7.94 $ - Granted during the period 175,246 $ 8.61 10.00 - Canceled during the period (134,476 ) $ 10.47 2.87 - Stock options outstanding on September 30, 2021 447,796 $ 11.55 7.57 - Exercisable on September 30, 2021 280,272 $ 13.76 6.78 $ - Non-vested stock options outstanding on January 1, 2021 274,065 $ 9.90 8.42 - Granted during the period 175,246 $ 8.61 10.00 - Vested during the period (185,870 ) $ 10.38 - - Canceled during the period (95,917 ) $ - - - Non-vested stock options outstanding on September 30, 2021 167,524 $ 8.44 8.87 $ - As of September 30, 2021, 1.85 3 MS1819. MS1819 MS1819 December 31, 2021. As of September 30, 2020, of.8.75 2 2 2 December 31, 2021. |
Note 14 - Agreements
Note 14 - Agreements | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Agreements Disclosure [Text Block] | Note 14 Agreements License Agreement with First Wave Bio, Inc. (FWB) On December 31, 2020, Niclosamide Product 19 In consideration of the license and other rights granted by FWB, the Company agreed to pay FWB a $9.0 million upfront cash payment due within 10 January 2021 June 30, 2021, July 2021. September 30, 2021, 19 five December 31, 2020, On January 8, 2021, FWB Purchase Agreement The conversion price of the Series C Preferred Stock was determined to be beneficial and, as a result, the Company recorded a deemed dividend of approximately $230,000 equal to the intrinsic value of the beneficial conversion feature and recognized on the issuance date and recorded as a reduction of income available to common stockholders in computing basic and diluted loss per share. Upon the 2021 February 24, 2021, December 31, 2020 Following the 2021 Upon consummating the FWB Merger on September 13, 2021, Mayoly Agreement In March 2019, Mayoly Mayoly APA MS1819. JDLA MS1819 TransChem Sublicense In August 2017, 5’methylthioadenosine TransChem Licensed Patents TransChem Sublicense Agreement March 2020, sixty 60 September 30, 2021 |
Note 15 - Leases
Note 15 - Leases | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | Note 15 Leases The Company leases its offices and research facilities under operating leases which are subject to various rent provisions and escalation clauses. Effective June 1, 2021, sixty-three 777 502, 33431. The Company’s leases expire at various dates through 2026. not Lease expense amounted to approximately $79,000 and $55,000, respectively, for the three September 30, 2021, 2020. Lease expense amounted to approximately $186,000 and $129,000, respectively, for the nine September 30, 2021, 2020. The weighted-average remaining lease term and weighted-average discount rate under operating leases on September 30, 2021, September 30, 2021 Lease term and discount rate Weighted-average remaining lease term (years) 4.5 Weighted-average discount rate 6.91 % Maturities of operating lease liabilities on September 30, 2021, 2021 $ 57,019 2022 81,254 2023 83,691 2024 86,202 2025 88,788 Thereafter 60,593 Total lease payments 457,547 Less imputed interest (67,064 ) Present value of lease liabilities $ 390,483 |
Note 16 - Income Taxes
Note 16 - Income Taxes | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 16 The Company did not nine September 30, 2021 2020 December 31, 2021 2020, On September 30, 2021, December 31, 2020, 740, Accounting for Income Taxes |
Note 17 - Net Loss Per Common S
Note 17 - Net Loss Per Common Share | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | Note 17 Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not On September 30, 2021, not September 30, 2021, not January 2021 At September 30, 2020, not At September 30, 2020, not |
Note 18 - Employee Benefit Plan
Note 18 - Employee Benefit Plans | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 18 401 Since 2015, 401 All employees are eligible to participate in the plan. Employees may 100% first may Employer contributions under this 401 three September 30, 2021 2020, Employer contributions under this 401 nine September 30, 2021 2020, |
Note 19 - Subsequent Events
Note 19 - Subsequent Events | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 19 ATM Agreement Sales On October 4, 2021, first 2 Achievement of Milestone pursuant to FWB Merger Agreement On October 4, 2021, first 2 $2.0 $17.0 Most Favored Nations (MFN) Exchange Right Subsequent to September 30, 2021, FWB Payments Fortis Advisors LLC is the hired representative (in such capacity, the “ Representative October 29, 2021, October 28, 2021 November 15, 2021, January 2022 August 2022 September 2022 July 2023 8 September 13, 2021, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The accompanying unaudited consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets, and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three September 30, 2021, December 31, 2020, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may September 30, 2021, December 31, 2020, one not The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. |
Debt, Policy [Policy Text Block] | Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method. |
Compensation Related Costs, Policy [Policy Text Block] | Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018 07, |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements The Company follows Accounting Standards Codification ( ASC 820 10, ( ASC 820 As a basis for considering such assumptions, a three Level 1: Level 2: Level 3: no In certain cases, the inputs used to measure fair value may The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. |
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] | Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may not September 30, 2021. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years |
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, ( ASC 360 may not not September 30, 2021. |
Income Tax, Policy [Policy Text Block] | Income Taxes Income taxes are recorded in accordance with ASC 740, ( ASC 740 not not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not September 30, 2021 December 31, 2020, not three |
Lessee, Leases [Policy Text Block] | Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU not may 15 |
License Agreement [Policy Text Block] | License Agreements As more fully discussed in Note 14, FWB License Agreement 19 19 no no September 13, 2021, |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third third CMC MS1819 Research and Development Intellectual Property Acquired The Company concluded that its acquisition of FWB completed on September 13, 2021 805, not The former FWB stockholders are also entitled to (i) up to $207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. The potential milestone payments and revenue share are not September 30, 2021. may |
Share-based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The Company’s board of directors (the “ Board 2014 2014 May 12, 2014, 2020 September 11, 2020 ( 2020 2020 no 2014 718, ASC 718 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In August 2020, 2020 06 SEC December 15, 2023. |
Note 3 - Fair Value Disclosur_2
Note 3 - Fair Value Disclosures (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value September 30, 2021: Cash and cash equivalents $ 7,210,645 $ 6,709,028 $ 501,617 $ - $ 7,210,645 December 31, 2020: Cash and cash equivalents $ 6,062,141 $ 3,000,184 $ 3,061,957 $ - $ 6,062,141 Other receivables $ 551,489 $ - $ - $ 551,489 $ 551,489 Note payable $ 552,405 $ - $ - $ 552,405 $ 552,405 |
Note 5 - Property, Equipment _2
Note 5 - Property, Equipment and Leasehold Improvements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | September 30, December 31, 2021 2020 Laboratory equipment $ - $ 2,410 Computer equipment and software 11,540 19,676 Office equipment 48,277 5,483 Leasehold improvements 28,000 29,163 Total property, plant, and equipment 87,817 56,732 Less accumulated depreciation (7,430 ) (38,403 ) Property, plant and equipment, net $ 80,387 $ 18,329 |
Note 6 - Intangible Assets an_2
Note 6 - Intangible Assets and Goodwill (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Patents [Table Text Block] | Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 449,280 Due to Mayoly at December 31, 2020 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745 |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | September 30, December 31, 2021 2020 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (1,318,870 ) (923,209 ) Patents, net $ 2,483,875 $ 2,879,536 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | 2021 (balance of year) $ 131,887 2022 527,548 2023 527,548 2024 527,548 2025 527,548 2026 241,796 Total $ 2,483,875 |
Schedule of Goodwill [Table Text Block] | Goodwill Balance on January 1, 2020 $ 1,886,686 Foreign currency translation 167,362 Balance on December 31, 2020 2,054,048 Foreign currency translation (109,306 ) Balance on September 30, 2021 $ 1,944,742 |
Note 7 - Accounts Payable and_2
Note 7 - Accounts Payable and Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Other Assets and Other Liabilities [Table Text Block] | September 30, December 31, 2021 2020 Trade payables $ 18,447,834 $ 1,558,591 Accrued expenses 135,072 127,012 Total accounts payable and accrued expenses $ 18,582,906 $ 1,685,603 |
Note 10 - Other Liabilities (Ta
Note 10 - Other Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Other Liabilities [Table Text Block] | September 30, December 31, 2021 2020 Current Lease liabilities $ 94,794 $ 57,417 Other liabilities 71,497 - $ 166,291 $ 57,417 Long-term Lease liabilities $ 295,689 $ 19,123 $ 295,689 $ 19,123 |
Note 12 - Warrants (Tables)
Note 12 - Warrants (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Exercise Weighted Price Per Average Warrants Share Price Warrants outstanding and exercisable on January 1, 2020 537,828 $10.70 - 73.70 $ 25.30 Granted during the period 1,988,165 $8.50 - 14.20 $ 8.80 Expired during the period (5,977 ) $32.50 - 73.70 $ 51.50 Exercised during the period - - - Warrants outstanding and exercisable on September 30, 2020 2,520,016 $8.50 - 73.70 $ 12.20 Warrants outstanding and exercisable on January 1, 2021 2,517,722 $8.50 - 73.70 $ 12.20 Granted during the period 3,995,602 $0.01 - 16.90 $ 7.77 Expired during the period (51,061 ) - - Exercised during the period (952,588 ) - - Warrants outstanding and exercisable on September 30, 2021 5,509,675 $6.87 - 66.00 $ 9.96 |
Schedule of Warrants by Exercise Price [Table Text Block] | Exercise Price Number of Shares Under Warrants Weighted Average Remaining Contract Life in Years Weighted Average Exercise Price $ 0.00 - 9.99 4,482,860 4.40 $ 10.00 - 19.99 840,745 3.62 $ 20.00 - 29.99 32,003 1.82 $ 30.00 - 39.99 61,155 0.61 $ 40.00 - 49.99 16,425 0.53 $ 50.00 - 59.99 72,714 0.47 $ 60.00 - 69.99 3,773 0.17 Totals 5,509,675 4.16 $ 9.96 |
Schedule of Warrant Assumptions [Table Text Block] | September 30, 2021 Expected life (in years) 5.19 Volatility 83.8 - 90.8 % Risk-free interest rate 0.28 - 1.67 Dividend yield -% |
Note 13 - Stock Options (Tables
Note 13 - Stock Options (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | September 30, 2021 Contractual term (in years) 10 Volatility 83.8 - 90.6 % Risk-free interest rate 83.9 - 1.69 Dividend yield - % |
Share-based Payment Arrangement, Activity [Table Text Block] | Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2020 167,750 $ 21.70 5.37 $ - Granted during the period 287,001 $ 8.90 9.79 - Canceled during the period (23,500 ) $ 19.40 3.28 - Stock options outstanding on September 30, 2020 431,251 $ 13.80 6.52 $ - Exercisable on September 30, 2020 131,275 $ 22.20 6.09 $ - Non-vested stock options outstanding on January 1, 2020 88,350 $ 13.30 6.26 $ - Granted during the period 287,001 $ 10.00 10.00 - Vested during the period (59,375 ) $ 25.90 6.88 - Canceled during the period (16,000 ) $ 13.00 7.10 - Non-vested stock options outstanding on September 30, 2020 299,976 $ 9.80 8.75 $ - Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2021 407,026 12.46 7.94 $ - Granted during the period 175,246 $ 8.61 10.00 - Canceled during the period (134,476 ) $ 10.47 2.87 - Stock options outstanding on September 30, 2021 447,796 $ 11.55 7.57 - Exercisable on September 30, 2021 280,272 $ 13.76 6.78 $ - Non-vested stock options outstanding on January 1, 2021 274,065 $ 9.90 8.42 - Granted during the period 175,246 $ 8.61 10.00 - Vested during the period (185,870 ) $ 10.38 - - Canceled during the period (95,917 ) $ - - - Non-vested stock options outstanding on September 30, 2021 167,524 $ 8.44 8.87 $ - |
Note 15 - Leases (Tables)
Note 15 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Lease, Cost [Table Text Block] | September 30, 2021 Lease term and discount rate Weighted-average remaining lease term (years) 4.5 Weighted-average discount rate 6.91 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2021 $ 57,019 2022 81,254 2023 83,691 2024 86,202 2025 88,788 Thereafter 60,593 Total lease payments 457,547 Less imputed interest (67,064 ) Present value of lease liabilities $ 390,483 |
Note 1 - The Company and Basi_2
Note 1 - The Company and Basis of Presentation (Details Textual) | Nov. 15, 2021USD ($) | Sep. 13, 2021 | Sep. 30, 2021USD ($) | Aug. 31, 2022USD ($) | Aug. 30, 2022USD ($) | Sep. 30, 2021USD ($) | Jul. 31, 2023USD ($) | Dec. 31, 2020USD ($) |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | |||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 7,210,645 | $ 7,210,645 | $ 6,062,141 | |||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (142,731,560) | $ (142,731,560) | $ (95,366,198) | |||||
Fortis Advisors Complaint [Member] | Forecast [Member] | ||||||||
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment | $ 500,000 | $ 500,000 | $ 1,000,000 | |||||
Fortis Advisors Complaint [Member] | Subsequent Event [Member] | ||||||||
Litigation Settlement, Amount Awarded to Other Party Immediately | $ 2,000,000 | |||||||
Litigation Settlement, Amount Awarded to Other Party | $ 17,000,000 | |||||||
AzurRx SAS [Member] | ||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 10.00% | 10.00% | ||||||
Reverse Stock Split [Member] | ||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | 10 |
Note 2 - Significant Accounti_2
Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements (Details Textual) - USD ($) | Sep. 30, 2021 | Sep. 13, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 |
Cash, Uninsured Amount | $ 300,000 | $ 300,000 | $ 2,700,000 | ||
Payments to Acquire Intangible Assets | 10,250,000 | $ 0 | |||
First Wave License Agreement [Member] | |||||
Asset Acquisition, Consideration Transferred, Total | 13,300,000 | ||||
Payments to Acquire Intangible Assets | 10,300,000 | ||||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 3,000,000 | ||||
FWB [Member] | |||||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 4,000,000 | ||||
FWB [Member] | Development Achievement Threshold [Member] | |||||
Asset Acquisition, Potential Milestone Payments | $ 207,000,000 | ||||
Asset Acquisition, Consideration Transferred, Contingent Consideration | $ 0 | ||||
Patents [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years 2 months 12 days |
Note 3 - Fair Value Disclosur_3
Note 3 - Fair Value Disclosures (Details Textual) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 7,210,645 | $ 6,062,141 |
Money Market Funds [Member] | ||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 6,700,000 | $ 3,000,000 |
Note 3 - Fair Value Disclosur_4
Note 3 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 7,210,645 | $ 6,062,141 |
Other receivables | 551,489 | |
Note payable | 552,405 | |
Estimate of Fair Value Measurement [Member] | ||
Cash and cash equivalents | 7,210,645 | 6,062,141 |
Other receivables | 551,489 | |
Note payable | 552,405 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 6,709,028 | 3,000,184 |
Other receivables | 0 | |
Note payable | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 501,617 | 3,061,957 |
Other receivables | 0 | |
Note payable | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | $ 0 | 0 |
Other receivables | 551,489 | |
Note payable | $ 552,405 |
Note 4 - Asset Acquisition (Det
Note 4 - Asset Acquisition (Details Textual) - USD ($) | Mar. 31, 2022 | Nov. 15, 2021 | Sep. 30, 2021 | Sep. 13, 2021 | Aug. 31, 2022 | Aug. 30, 2022 | Jul. 31, 2023 |
Fortis Advisors Complaint [Member] | Forecast [Member] | |||||||
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment | $ 500,000 | $ 500,000 | $ 1,000,000 | ||||
Subsequent Event [Member] | Fortis Advisors Complaint [Member] | |||||||
Litigation Settlement, Amount Awarded to Other Party Immediately | $ 2,000,000 | ||||||
Litigation Settlement, Amount Awarded to Other Party | $ 17,000,000 | ||||||
FWB [Member] | |||||||
Payments to Acquire Productive Assets, Total | $ 3,000,000 | ||||||
Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 624,025 | ||||||
Asset Acquisition, Consideration Transferred, Liabilities Incurred | $ 8,000,000 | ||||||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 4,000,000 | ||||||
Shares Issued, Price Per Share (in dollars per share) | $ 6.41 | ||||||
FWB [Member] | Research and Development Expense [Member] | |||||||
Asset Acquisition, Consideration Transferred, Non-contingent Consideration | $ 21,300,000 | ||||||
FWB [Member] | General and Administrative Expense [Member] | |||||||
Asset Acquisition, Consideration Transferred, Transaction Cost | 900,000 | ||||||
FWB [Member] | Development Achievement Threshold [Member] | |||||||
Asset Acquisition, Potential Milestone Payments | $ 207,000,000 | ||||||
Asset Acquisition, Consideration Transferred, Contingent Consideration Percent | 25.00% | ||||||
Asset Acquisition, Consideration Transferred, Contingent Consideration | $ 0 | ||||||
FWB [Member] | Patent Infringement [Member] | |||||||
Asset Acquisition, Consideration Transferred, Percent | 10.00% | ||||||
FWB [Member] | Subsequent Event [Member] | |||||||
Asset Acquisition, Consideration Transferred, Liabilities Incurred | $ 7,000,000 | ||||||
Stock Cancelled During Period, Shares, Acquisitions (in shares) | 332,913 |
Note 5 - Property, Equipment _3
Note 5 - Property, Equipment and Leasehold Improvements (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Depreciation, Total | $ 6,000 | $ 8,000 | $ 9,390 | $ 26,556 |
Leasehold Improvements [Member] | ||||
Property, Plant and Equipment, Disposals | $ 29,000 |
Note 5 - Property, Equipment _4
Note 5 - Property, Equipment and Leasehold Improvements - Property, Equipment and Leasehold Improvements (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Property, plant and equipment, gross | $ 87,817 | $ 56,732 |
Less accumulated depreciation | (7,430) | (38,403) |
Property, plant and equipment, net | 80,387 | 18,329 |
Laboratory Equipment [Member] | ||
Property, plant and equipment, gross | 0 | 2,410 |
Computer Equipment [Member] | ||
Property, plant and equipment, gross | 11,540 | 19,676 |
Office Equipment [Member] | ||
Property, plant and equipment, gross | 48,277 | 5,483 |
Leasehold Improvements [Member] | ||
Property, plant and equipment, gross | $ 28,000 | $ 29,163 |
Note 6 - Intangible Assets an_3
Note 6 - Intangible Assets and Goodwill (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Finite-Lived Intangible Assets, Net, Ending Balance | $ 2,483,875 | $ 2,483,875 | $ 2,879,536 | ||
Amortization of Intangible Assets, Total | 132,000 | $ 132,000 | 396,000 | $ 396,000 | |
Patents [Member] | |||||
Finite-Lived Intangible Assets, Net, Ending Balance | 2,483,875 | 2,483,875 | $ 2,879,536 | ||
Patents [Member] | Mayoly [Member] | |||||
Finite-Lived Intangible Assets, Net, Ending Balance | $ 3,800,000 | $ 3,800,000 |
Note 6 - Intangible Assets an_4
Note 6 - Intangible Assets and Goodwill - Patents (Details) - Patents [Member] - USD ($) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2021 | Dec. 31, 2019 | Dec. 31, 2020 | Mar. 31, 2019 | |
Patents | $ 3,802,745 | $ 3,802,745 | ||
Mayoly [Member] | ||||
Patents | 3,802,745 | $ 1,740,959 | ||
Patents | $ 1,219,386 | $ 449,280 | $ 393,120 |
Note 6 - Intangible Assets an_5
Note 6 - Intangible Assets and Goodwill - Intangible Assets (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Total | $ 2,483,875 | $ 2,879,536 |
Patents [Member] | ||
Patents | 3,802,745 | 3,802,745 |
Less accumulated amortization | (1,318,870) | (923,209) |
Total | $ 2,483,875 | $ 2,879,536 |
Note 6 - Intangible Assets an_6
Note 6 - Intangible Assets and Goodwill - Amortization Expense (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
2021 (balance of year) | $ 131,887 | |
2022 | 527,548 | |
2023 | 527,548 | |
2024 | 527,548 | |
2025 | 527,548 | |
2026 | 241,796 | |
Total | $ 2,483,875 | $ 2,879,536 |
Note 6 - Intangible Assets an_7
Note 6 - Intangible Assets and Goodwill - Goodwill (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Dec. 31, 2020 | |
Balance | $ 2,054,048 | $ 1,886,686 |
Foreign currency translation | (109,306) | 167,362 |
Balance | $ 1,944,742 | $ 2,054,048 |
Note 7 - Accounts Payable and_3
Note 7 - Accounts Payable and Accrued Expenses (Details Textual) $ in Millions | Sep. 30, 2021USD ($) |
FWB [Member] | |
Asset Acquisition, Acquired Receivables | $ 15 |
Note 7 - Accounts Payable and_4
Note 7 - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Trade payables | $ 18,447,834 | $ 1,558,591 |
Accrued expenses | 135,072 | 127,012 |
Total accounts payable and accrued expenses | $ 18,582,906 | $ 1,685,603 |
Note 8 - Note Payable (Details
Note 8 - Note Payable (Details Textual) - USD ($) | Nov. 30, 2020 | Sep. 30, 2021 | Dec. 31, 2020 |
Notes Payable, Current, Total | $ 0 | $ 552,405 | |
Financing Agreement for Directors and Officer's Liability Insurance [Member] | |||
Debt Instrument, Term (Month) | 9 months | ||
Debt Instrument, Face Amount | $ 620,000 | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | ||
Debt Instrument, Periodic Payment, Total | $ 70,000 | ||
Notes Payable, Current, Total | $ 0 | $ 552,000 |
Note 9 - Convertible Debt (Deta
Note 9 - Convertible Debt (Details Textual) - USD ($) | Jan. 09, 2021 | Jul. 16, 2020 | Jan. 09, 2020 | Feb. 14, 2019 | Jan. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2020 | Jun. 01, 2020 | Jan. 02, 2020 | Dec. 20, 2019 |
Note Warrants [Member] | |||||||||||
Class of Warrant or Right, Exercise, Percentage of Common Stock Converted from Debt Instrument | 50.00% | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10.70 | $ 10.70 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 181,325 | ||||||||||
Placement Agent Warrants [Member] | |||||||||||
Class of Warrant or Right, Exercise, Percentage of Common Stock Converted from Debt Instrument | 7.00% | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.60 | $ 14.20 | $ 12.10 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | 5 years | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 19,973 | 15,823 | 19,973 | 19,973 | 4,149 | ||||||
Placement Agent Warrants, Exercise Price 12.10 [Member] | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 12.10 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,149 | ||||||||||
Placement Agent Warrants, Exercise Price 14.20 [Member] | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 14.20 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 15,823 | ||||||||||
ADEC Note 1 [Member] | |||||||||||
Debt Instrument, Face Amount | $ 1,000,000 | ||||||||||
ADEC Notes [Member] | |||||||||||
Proceeds from Issuance of Long-term Debt, Total | $ 2,000,000 | ||||||||||
Repayments of Long-term Debt, Total | $ 450,000 | $ 1,550,000 | |||||||||
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total | $ 104,000 | ||||||||||
Promissory Notes [Member] | |||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | ||||||||||
Proceeds from Issuance of Long-term Debt, Total | $ 3,500,000 | ||||||||||
Repayments of Long-term Debt, Total | $ 25,000 | ||||||||||
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total | $ 1,000 | ||||||||||
Debt Instrument, Maximum Principal Offering | $ 8,000,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.00% | ||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 9.70 | ||||||||||
Debt Instrument, Fee Amount | $ 277,000 | ||||||||||
Debt Instrument, Fee, Percentage of Principal | 9.00% | ||||||||||
Debt Instrument, Fee, Percentage of Gross Proceeds | 1.00% | ||||||||||
Debt Instrument, Fair Value Disclosure, Total | 2,400,000 | ||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 1,800,000 | ||||||||||
Debt Issuance Costs, Net, Total | 500,000 | ||||||||||
Long-term Debt, Gross | $ 100,000 | ||||||||||
Interest Expense, Debt, Total | $ 400,000 | $ 4,900,000 | |||||||||
Amortization of Debt Discount (Premium) | 120,000 | 1,500,000 | |||||||||
Amortization of Beneficial Conversion Feature | 193,000 | 2,300,000 | |||||||||
Amortization of Debt Issuance Costs | 63,000 | 800,000 | |||||||||
Debt Instrument, Accrued Interest Expense | $ 27,000 | $ 300,000 | |||||||||
Promissory Notes [Member] | Edward J. Borkowski [Member] | |||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 10.70 | ||||||||||
Long-term Debt, Gross | $ 100,000 |
Note 10 - Other Liabilities - O
Note 10 - Other Liabilities - Other Liabilities (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Lease liabilities | $ 94,794 | $ 57,417 |
Other liabilities | 71,497 | 0 |
Other Liabilities, Current, Total | 166,291 | 57,417 |
Lease liabilities | 295,689 | 19,123 |
Other Liabilities, Noncurrent, Total | $ 295,689 | $ 19,123 |
Note 11 - Equity (Details Textu
Note 11 - Equity (Details Textual) | Sep. 30, 2021USD ($)$ / sharesshares | Sep. 13, 2021shares | Jul. 22, 2021USD ($)$ / sharesshares | May 26, 2021shares | Mar. 10, 2021USD ($)$ / sharesshares | Feb. 24, 2021USD ($)shares | Jan. 06, 2021USD ($)$ / sharesshares | Sep. 11, 2020shares | Jul. 16, 2020USD ($)$ / sharesshares | Nov. 01, 2019USD ($)shares | Jun. 09, 2021$ / sharesshares | Feb. 23, 2021$ / sharesshares | Sep. 30, 2021USD ($)$ / sharesshares | Sep. 30, 2020USD ($)$ / sharesshares | Jun. 09, 2021$ / sharesshares | Sep. 30, 2021USD ($)$ / sharesshares | Sep. 30, 2020USD ($)$ / sharesshares | Feb. 28, 2021shares | Jan. 05, 2021shares | Dec. 31, 2020$ / sharesshares | Dec. 31, 2019$ / sharesshares | Dec. 20, 2019$ / sharesshares | Feb. 24, 2019shares |
Common Stock, Shares Authorized (in shares) | 25,000,000 | 25,000,000 | 25,000,000 | 250,000,000 | 25,000,000 | 150,000,000 | 15,000,000 | 25,000,000 | |||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | ||||||||||||||||||||||
Common Stock, Shares, Issued, Total (in shares) | 11,115,228 | 11,115,228 | 11,115,228 | 3,115,031 | |||||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 11,115,228 | 11,115,228 | 11,115,228 | 3,115,031 | |||||||||||||||||||
Preferred Stock, Shares Issued, Total (in shares) | 676.05 | 676.05 | 676.05 | ||||||||||||||||||||
Preferred Stock, Remaining Authorized but Unissued (in shares) | 9,919,805.19 | 9,919,805.19 | 9,919,805.19 | ||||||||||||||||||||
Dividends Payable | $ | $ 349,132 | $ 349,132 | $ 408,043 | $ 349,132 | $ 408,043 | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | 7,150,847 | 8,325,195 | 988,348 | ||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 123,549 | 22,500 | $ 1,215,859 | 109,605 | |||||||||||||||||||
Stock Issued During Period, Shares, Acquisitions (in shares) | 624,025 | ||||||||||||||||||||||
Stock Issued During Period, Shares, Treasury Stock Reissued (in shares) | 332,913 | ||||||||||||||||||||||
Stock Issued During Period, Shares, Settlement (in shares) | 7,500 | ||||||||||||||||||||||
Stock Issued During Period, Value, Settlement | $ | 85,770 | $ 94,499 | $ 85,770 | ||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 952,588 | 0 | |||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 1,100,000 | $ 1,100,000 | 2,200,000 | $ 1,100,000 | $ 2,200,000 | ||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 3,995,602 | 1,988,165 | |||||||||||||||||||||
Deemed Dividends, Preferred Stock Issuances | $ | $ 0 | $ 8,155,212 | $ 4,507,125 | $ 8,155,212 | |||||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 5,977 | ||||||||||||||||||||||
Common Stock, Contingently Issuable (in shares) | 1,633,720 | 1,633,720 | 1,633,720 | ||||||||||||||||||||
Shares Contingently Issuable, Price Per Share (in dollars per share) | $ / shares | $ 3.40 | $ 3.40 | $ 3.40 | ||||||||||||||||||||
Deemed Dividends, Preferred Stock Exchanges | $ | $ 0 | $ 0 | $ 21,008,253 | 0 | |||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 18,156,050 | $ 988,348 | |||||||||||||||||||||
Promissory Notes [Member] | |||||||||||||||||||||||
Repayments of Long-term Debt, Total | $ | $ 25,000 | ||||||||||||||||||||||
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total | $ | 1,000 | ||||||||||||||||||||||
Notes Payable, Total | $ | $ 0 | ||||||||||||||||||||||
Class of Warrant or Rights, Investor and Pre_funded Warrants [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, Exercise of Warrants (in shares) | 945,644 | ||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 3,991,882 | ||||||||||||||||||||||
January 2021 Investor Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 9,526,209 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 8 | $ 8 | $ 8 | $ 8 | $ 8 | $ 8 | |||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,066,666 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Contingently Issuable (in shares) | 740,612 | 740,612 | 740,612 | ||||||||||||||||||||
Exchange Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 177,293 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 8.50 | ||||||||||||||||||||||
Class of Warrant or Right, Issued, Percentage of Stock Issued Upon Conversion | 25.00% | ||||||||||||||||||||||
January 2021 Placement Agent Warrants [Member] | |||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 7.50 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 74,666 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 9.375 | ||||||||||||||||||||||
Equity Offering, Management Fee, Percentage of Gross Proceeds | 1.00% | ||||||||||||||||||||||
Placement Agent Fee and Management Fee | $ | $ 700,000 | ||||||||||||||||||||||
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering | 7.00% | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price | 125.00% | ||||||||||||||||||||||
March 2021 Prefunded Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 205,854 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.01 | ||||||||||||||||||||||
Equity Offering, Maximum Offering Shares (in shares) | 580,000 | ||||||||||||||||||||||
The March 2021 Offering [Member] | |||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 12.725 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 392,927 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 12.10 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||||
March 2021 Placement Agent Warrants [Member] | |||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 12.725 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 55,008 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.906 | ||||||||||||||||||||||
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering | 7.00% | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price | 125.00% | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||||
Wainwright Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.875 | ||||||||||||||||||||||
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering | 7.00% | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price | 125.00% | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 73,181 | ||||||||||||||||||||||
Series C Preferred Stock Converted into Common Stock [Member] | |||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 7.70 | ||||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 33,699 | 1,316,662 | 3,125,460 | ||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 334.46 | 13,166.62 | 33,097.10 | ||||||||||||||||||||
Conversion of Stock, Amount Converted | $ | $ 2,000 | $ 24,700,000 | |||||||||||||||||||||
Conversion of Stock, Amount Converted, Accrued Dividends | $ | $ 198,000 | ||||||||||||||||||||||
Series B Preferred Stock Converted into Common Stock [Member] | |||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 7.70 | $ 7.70 | |||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 34,127 | 258,278 | |||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 34.127448 | 258.08 | |||||||||||||||||||||
Conversion of Stock, Amount Converted | $ | $ 2 | ||||||||||||||||||||||
Conversion of Stock, Amount Converted, Accrued Dividends | $ | $ 3,551 | $ 3,000 | |||||||||||||||||||||
Common Stock Dividends, Shares (in shares) | 461 | ||||||||||||||||||||||
Series B Preferred Stock Converted into Series C Preferred Stock and Warrants [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 19,140.14 | ||||||||||||||||||||||
Conversion of Stock, Amount Converted | $ | $ 14,400,000 | ||||||||||||||||||||||
Preferred Stock, Issued, Convertible, Shares Issuable (in shares) | 1,914,024 | ||||||||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 563,915 | 1,914,024 | 1,914,024 | ||||||||||||||||||||
Conversion of Series C Preferred Stock to Common Stock [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 19,140.14 | ||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,839.76 | ||||||||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 1,914,014 | ||||||||||||||||||||||
Deemed Dividends, Preferred Stock Exchanges | $ | $ 21,000,000 | ||||||||||||||||||||||
Consultants [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 20,200 | 3,164 | 97,230 | ||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 124,000 | $ 25,000 | $ 1,200,000 | ||||||||||||||||||||
Consultants Or Outside Board [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | ||||||||||||||||||||||
Consultants 2 [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 13,284 | ||||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 112,000 | ||||||||||||||||||||||
Outside Board [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 10,593 | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 131,000 | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 12.40 | $ 12.40 | |||||||||||||||||||||
Exchange Investors [Member] | Promissory Notes Converted into Series B Preferred Stock and Warrants [Member] | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 937 | ||||||||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares) | 468,499 | ||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ | $ 6,900,000 | ||||||||||||||||||||||
Debt Conversion, Original Debt, Amount, Accrued Interest | $ | $ 300,000 | ||||||||||||||||||||||
Equity Line Agreement [Member] | Lincoln Park [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 48,716 | 0 | 149,519 | ||||||||||||||||||||
Stock Purchase Agreement, Maximum Value of Committed Shares | $ | $ 15,000,000 | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 297,000 | $ 0 | $ 988,000 | ||||||||||||||||||||
Stock Purchase Agreement, Committed Shares, Remaining Value | $ | $ 14,000,000 | ||||||||||||||||||||||
At The Market Offering Agreement [Member] | Wainwright [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,501,661 | 1,651,225 | |||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 7,400,000 | $ 8,600,000 | |||||||||||||||||||||
Stock Sales Agreement, Commission on Shares Sold, Percentage | 3.00% | ||||||||||||||||||||||
Stock Sales Agreement, Number of Shares Authorized (in shares) | 50,000,000 | ||||||||||||||||||||||
Stock Issued During Period, Issuance Costs | $ | $ 228,000 | $ 274,000 | |||||||||||||||||||||
Series B Purchase Agreement [Member] | Series B Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,456,282 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 8.50 | ||||||||||||||||||||||
Class of Warrant or Right, Issued, Percentage of Stock Issued Upon Conversion | 50.00% | ||||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 987,783 | ||||||||||||||||||||||
Series B Private Placement [Member] | |||||||||||||||||||||||
Proceeds from Issuance of Equity, Gross | $ | $ 15,200,000 | ||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 13,200,000 | ||||||||||||||||||||||
January 2021 Offerings [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,066,666 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 8 | ||||||||||||||||||||||
Proceeds from Issuance of Equity, Gross | $ | $ 8,000,000 | ||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 7,100,000 | ||||||||||||||||||||||
Equity Offerings, Placement Agent Cash Fee, Percentage of Gross Proceeds | 8.00% | ||||||||||||||||||||||
Non-accountable Expenses | $ | $ 35,000 | ||||||||||||||||||||||
Legal Fees | $ | 125,000 | ||||||||||||||||||||||
Clearance Fees | $ | 12,900 | ||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | 900,000 | ||||||||||||||||||||||
Deemed Dividends, Preferred Stock Issuances | $ | 4,300,000 | ||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ | 900,000 | ||||||||||||||||||||||
January 2021 Offerings [Member] | January 2021 Investor Warrants [Member] | |||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | 3,400,000 | ||||||||||||||||||||||
March 2021 Offering [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 55,009 | ||||||||||||||||||||||
Proceeds from Issuance of Equity, Gross | $ | $ 10,000,000 | ||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 9,100,000 | ||||||||||||||||||||||
Equity Offerings, Placement Agent Cash Fee, Percentage of Gross Proceeds | 8.00% | ||||||||||||||||||||||
Non-accountable Expenses | $ | $ 35,000 | ||||||||||||||||||||||
Legal Fees | $ | 50,000 | ||||||||||||||||||||||
Clearance Fees | $ | 16,000 | ||||||||||||||||||||||
Placement Agent Fee | $ | $ 800,000 | ||||||||||||||||||||||
Underwriting Agreement [Member] | Wainwright [Member] | |||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 5.50 | ||||||||||||||||||||||
Equity Offering, Maximum Offering Shares (in shares) | 909,091 | ||||||||||||||||||||||
Non-accountable Expenses | $ | $ 35,000 | ||||||||||||||||||||||
Legal Fees | $ | 125,000 | ||||||||||||||||||||||
Clearance Fees | $ | 15,950 | ||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 5,100,000 | ||||||||||||||||||||||
Equity Offering, Underwriting Discount, Percentage of Gross Proceeds | 8.00% | ||||||||||||||||||||||
Over-Allotment Option [Member] | Wainwright [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 136,363 | ||||||||||||||||||||||
Restricted Stock [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | 174 | 0 | 1,008 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Grant Date, Fair Value | $ | $ 6,000 | $ 36,000 | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 0 | 400 | |||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 394,000 | $ 394,000 | $ 394,000 | $ 394,000 | $ 394,000 | ||||||||||||||||||
Restricted Stock [Member] | First Commercial Sale of MS1819 [Member] | |||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | 197,000 | 197,000 | 197,000 | 197,000 | 197,000 | ||||||||||||||||||
Restricted Stock [Member] | Vests Upon Total Market Capitalization Exceeding One Million [Member] | |||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 197,000 | $ 197,000 | $ 197,000 | 197,000 | 197,000 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Unrecognized Costs, Vesting Milestone, Amount | $ | $ 1 | $ 1 | |||||||||||||||||||||
The 2014 Omnibus Equity Incentive Plan [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 79,500 | ||||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 38,700 | 38,700 | 38,700 | ||||||||||||||||||||
The 2014 Omnibus Equity Incentive Plan [Member] | Restricted Stock [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 272,050 | 272,050 | 272,050 | ||||||||||||||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 175,246 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,000,000 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase | 10.00% | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares, Available (in shares) | 1,000,000 | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 176,246 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares, Available, Net of Issuance (in shares) | 823,754 | ||||||||||||||||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,500,000 | ||||||||||||||||||||||
July 2021 Offering [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 1,045,454 | ||||||||||||||||||||||
March 2021 Offering [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,625,454 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 5,194.81 | 5,194.805195 | 5,194.81 | 5,194.81 | 5,194.81 | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||
Preferred Stock, Shares Issued, Total (in shares) | 676.05 | 676.05 | 676.05 | 2,773.6 | |||||||||||||||||||
Preferred Stock, Remaining Authorized but Unissued (in shares) | 2,168.14 | 2,168.14 | 2,168.14 | ||||||||||||||||||||
Preferred Stock, Stated Value Per Share (in dollars per share) | $ / shares | $ 7,700 | $ 7,700 | $ 7,700 | ||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 9.00% | ||||||||||||||||||||||
Preferred Stock, Dividends, Payment of Fractional Shares Amount | $ | $ 100 | ||||||||||||||||||||||
Dividends Payable | $ | $ 349,000 | $ 349,000 | 349,000 | ||||||||||||||||||||
Preferred Stock, Liquidation Preference, Value | $ | $ 5,600,000 | $ 5,600,000 | $ 5,600,000 | ||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 7.70 | $ 7.70 | $ 7.70 | ||||||||||||||||||||
Preferred Stock, Convertible, Threshold Percentage of Stock Price Trigger | 250.00% | ||||||||||||||||||||||
Preferred Stock, Convertible, Stock Price Trigger (in dollars per share) | $ / shares | $ 19.25 | ||||||||||||||||||||||
Preferred Stock, Convertible, Threshold Consecutive Trading Days | 20 | ||||||||||||||||||||||
Preferred Stock, Convertible, Exceeding Percentage of Affiliates | 9.99% | ||||||||||||||||||||||
Preferred Stock, Convertible, Exceeding Percentage Holder | 19.99% | ||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,839.76 | 676.05 | |||||||||||||||||||||
Preferred Stock, Percentage of Stated Value, Repurchase Without Stockholder Approval | 150.00% | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 676.05 | 676.05 | 676.05 | 2,773.6 | |||||||||||||||||||
Dividends, Preferred Stock, Total | $ | $ 349,000 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | Exchange Investors [Member] | |||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 937,000 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | Series B Purchase Agreement [Member] | |||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | ||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 7.70 | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,912.583005 | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 7,700 | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 2,912,575 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | Series B Private Placement [Member] | |||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 1,975.58 | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1,975,574 | ||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 57,000 | 57,000 | 57,000 | 75,000 | 57,000 | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||
Preferred Stock, Shares Issued, Total (in shares) | 0 | 0 | 0 | 0 | |||||||||||||||||||
Preferred Stock, Remaining Authorized but Unissued (in shares) | 41,902.90 | 41,902.90 | 41,902.90 | ||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 33,446 | ||||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 334.46 | 0 | 0 | 0 | ||||||||||||||||||
Preferred Stock, Contingently Issuable (in shares) | 7,406 | 7,406 | 7,406 | ||||||||||||||||||||
Convertible Preferred Stock, Shares Issued Upon Conversion, Contingently Issuable (in shares) | 740,612 | 740,612 | 740,612 | ||||||||||||||||||||
Series C Preferred Stock [Member] | January 2021 Registered Direct Offering [Member] | |||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 7.50 | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 533,333 | ||||||||||||||||||||||
Equity Offering, Maximum Offering Shares (in shares) | 5,333.333 | ||||||||||||||||||||||
Equity Offering, Price Per Share (in dollars per share) | $ / shares | $ 750 | ||||||||||||||||||||||
Series C Preferred Stock [Member] | January 2021 Private Placement [Member] | |||||||||||||||||||||||
Equity Offering, Maximum Offering Shares (in shares) | 5,333.3333 | ||||||||||||||||||||||
Series C Preferred Stock [Member] | January 2021 Offerings [Member] | |||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 4,600,000 | ||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.87 | $ 6.87 | $ 8.50 | $ 6.87 | $ 8.50 | $ 8.50 | $ 10.70 | ||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 66 | $ 66 | $ 73.70 | $ 66 | $ 73.70 | $ 73.70 | $ 73.70 | ||||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | 10 | |||||||||||||||||||||
Stock Issued During Period, Shares, Reverse Stock Splits (in shares) | 1,706 | ||||||||||||||||||||||
Reverse Stock Split [Member] | Minimum [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 5 | ||||||||||||||||||||||
Reverse Stock Split [Member] | Maximum [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 |
Note 12 - Warrants (Details Tex
Note 12 - Warrants (Details Textual) - USD ($) | Mar. 10, 2021 | Feb. 08, 2021 | Jan. 06, 2021 | Jul. 16, 2020 | Jul. 14, 2020 | Jan. 09, 2020 | Feb. 24, 2021 | Jun. 09, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Jun. 09, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Jan. 09, 2021 | Dec. 31, 2020 | Jan. 02, 2020 | Dec. 31, 2019 | Dec. 20, 2019 |
Conversion of Stock, Warrants Issued (in shares) | 5,977 | |||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 3,995,602 | 1,988,165 | ||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 952,588 | 0 | ||||||||||||||||
Proceeds from Warrant Exercises | $ 4,906,630 | $ 0 | ||||||||||||||||
Class of Warrant or Right, Issued in Period, Weighted Average Fair Value Per Share (in dollars per share) | $ 8.85 | $ 8.80 | ||||||||||||||||
Minimum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.87 | $ 8.50 | 6.87 | 8.50 | $ 8.50 | $ 10.70 | ||||||||||||
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share) | 32.50 | |||||||||||||||||
Maximum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 66 | 73.70 | $ 66 | 73.70 | $ 73.70 | $ 73.70 | ||||||||||||
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share) | 73.70 | |||||||||||||||||
Series B Preferred Stock Converted into Series C Preferred Stock and Warrants [Member] | ||||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 563,915 | 1,914,024 | 1,914,024 | |||||||||||||||
Series C Preferred Stock Exchanged for Common Stock and Warrants [Member] | ||||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 193,333 | |||||||||||||||||
Common Stock Concerted into Series B Preferred Stock and Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.50 | $ 8.50 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 8,100,000 | |||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 145,628 | |||||||||||||||||
July 2021 Placement Agent Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 73,181 | 73,181 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.875 | $ 6.875 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 263,000 | |||||||||||||||||
January 2021 Investor Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8 | $ 8 | $ 8 | $ 8 | $ 8 | |||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 6,000,000 | $ 21,000,000 | $ 3,400,000 | |||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,066,666 | |||||||||||||||||
Adjustments to Additional Paid in Capital, Warrant Issued | $ 3,400,000 | |||||||||||||||||
Class of Warrant or Right, Prohibited Exercise (in shares) | 1,350,108 | |||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 9,526,209 | |||||||||||||||||
Class of Warrant or Right, Pre-funded [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 205,854 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | $ 0.01 | ||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 2,600,000 | $ 1,600,000 | ||||||||||||||||
January 2021 Placement Agent Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 74,666 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.375 | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 392,000 | |||||||||||||||||
March 2021 Investor Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 392,927 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 12.10 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 3,500,000 | |||||||||||||||||
March 2021 Placement Agent Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 55,008 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.906 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 453,000 | |||||||||||||||||
Warrants to Consultant, Subject to Service-based Milestone Vesting Conditions [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 20,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 16.90 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 4 years | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 214,000 | |||||||||||||||||
Class of Warrant or Right, Vested During Period (in shares) | 15,000 | 20,000 | ||||||||||||||||
Share-based Payment Arrangement, Expense | $ 161,000 | $ 214,000 | ||||||||||||||||
January and March 2021 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 952,620 | |||||||||||||||||
Stock Issued During Period, Shares, Exercise of Warrants (in shares) | 945,633 | |||||||||||||||||
Proceeds from Warrant Exercises | $ 4,900,000 | |||||||||||||||||
Note Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 181,325 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10.70 | $ 10.70 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 1,600,000 | |||||||||||||||||
Class of Warrant or Right, Vesting Period (Year) | 6 years | |||||||||||||||||
Placement Agent Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 15,823 | 19,973 | 19,973 | 19,973 | 4,149 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.60 | $ 14.20 | $ 12.10 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | 5 years | |||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 745,000 | $ 174,000 | ||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 137,745 | |||||||||||||||||
Exchange Warrant [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.50 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 1,000,000 | |||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 177,293 | |||||||||||||||||
Warrants in Connection With Settlement With Former CEO [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||
Class of Warrant or Right, Grant Date, Fair Value | $ 85,000 | |||||||||||||||||
Conversion of Stock, Warrants Issued (in shares) | 15,000 |
Note 12 - Warrants - Warrant Tr
Note 12 - Warrants - Warrant Transactions (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Warrants outstanding and exercisable (in shares) | 2,517,722 | 537,828 |
Granted during the period, warrants (in shares) | 3,995,602 | 1,988,165 |
Expired during the period, warrants (in shares) | (51,061) | (5,977) |
Exercised during the period, warrants (in shares) | (952,588) | 0 |
Warrants outstanding and exercisable (in shares) | 5,509,675 | 2,520,016 |
Minimum [Member] | ||
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | $ 8.50 | $ 10.70 |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 0.01 | 8.50 |
Expired during the period, exercise price per share, warrants (in dollars per share) | 32.50 | |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 6.87 | 8.50 |
Maximum [Member] | ||
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 73.70 | 73.70 |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 16.90 | 14.20 |
Expired during the period, exercise price per share, warrants (in dollars per share) | 73.70 | |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 66 | 73.70 |
Weighted Average [Member] | ||
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 12.20 | 25.30 |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | 7.77 | 8.80 |
Expired during the period, exercise price per share, warrants (in dollars per share) | 51.50 | |
Warrants outstanding and exercisable, exercise price per share (in dollars per share) | $ 9.96 | $ 12.20 |
Note 12 - Warrants - Warrants E
Note 12 - Warrants - Warrants Exerciseable (Details) | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Number of warrants under share (in shares) | shares | 5,509,675 |
Weighted average remaining contractual life (Year) | 4 years 1 month 28 days |
Weighted Average [Member] | |
Exercise Price (in dollars per share) | $ 9.96 |
Warrant One [Member] | |
Number of warrants under share (in shares) | shares | 4,482,860 |
Weighted average remaining contractual life (Year) | 4 years 4 months 24 days |
Warrant One [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 0 |
Warrant One [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 9.99 |
Warrant Two [Member] | |
Number of warrants under share (in shares) | shares | 840,745 |
Weighted average remaining contractual life (Year) | 3 years 7 months 13 days |
Warrant Two [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 10 |
Warrant Two [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 19.99 |
Warrant Three [Member] | |
Number of warrants under share (in shares) | shares | 32,003 |
Weighted average remaining contractual life (Year) | 1 year 9 months 25 days |
Warrant Three [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 20 |
Warrant Three [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 29.99 |
Warrant Four [Member] | |
Number of warrants under share (in shares) | shares | 61,155 |
Weighted average remaining contractual life (Year) | 7 months 9 days |
Warrant Four [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 30 |
Warrant Four [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 39.99 |
Warrant Five [Member] | |
Number of warrants under share (in shares) | shares | 16,425 |
Weighted average remaining contractual life (Year) | 6 months 10 days |
Warrant Five [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 40 |
Warrant Five [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 49.99 |
Warrant Six [Member] | |
Number of warrants under share (in shares) | shares | 72,714 |
Weighted average remaining contractual life (Year) | 5 months 19 days |
Warrant Six [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 50 |
Warrant Six [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 59.99 |
Warrant Seven [Member] | |
Number of warrants under share (in shares) | shares | 3,773 |
Weighted average remaining contractual life (Year) | 2 months 1 day |
Warrant Seven [Member] | Minimum [Member] | |
Exercise Price (in dollars per share) | $ 60 |
Warrant Seven [Member] | Maximum [Member] | |
Exercise Price (in dollars per share) | $ 69.99 |
Note 12 - Warrants - Weighted A
Note 12 - Warrants - Weighted Average Assumptions (Details) | Sep. 30, 2021 |
Measurement Input, Expected Term [Member] | |
Assumption | 5.19 |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Assumption | 0.838 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | |
Assumption | 0.908 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Assumption | 0.0028 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Assumption | 0.0167 |
Measurement Input, Expected Dividend Rate [Member] | |
Assumption | 0 |
Note 13 - Stock Options (Detail
Note 13 - Stock Options (Details Textual) - USD ($) | Sep. 30, 2021 | Jun. 30, 2021 | Sep. 30, 2020 | Jan. 02, 2020 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 |
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,100,000 | $ 2,200,000 | $ 2,200,000 | $ 1,100,000 | $ 2,200,000 | $ 1,100,000 | $ 2,200,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 23,500 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) | 167,524 | 167,524 | 167,524 | ||||||||
Minimum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 9.70 | ||||||||||
Maximum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 36 | ||||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | |||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 8.61 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 175,246 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 134,476 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 185,870 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) | 274,065 | ||||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 18,781 | 175,246 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ 102,000 | $ 403,000 | |||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | Minimum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | 5.80 | 6.40 | |||||||||
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | Maximum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 7.50 | 15.40 | |||||||||
The 2014 Omnibus Equity Incentive Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 30,000 | 3,500 | |||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 10.30 | $ 8.50 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 3 years | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 79,500 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ 23,000 | $ 24,000 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 0 | ||||||||||
Share-based Payment Arrangement, Expense | $ 25,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares) | 633 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) | 286 | ||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 24,000 | ||||||||||
The 2014 Omnibus Equity Incentive Plan [Member] | Minimum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | 8.50 | ||||||||||
The 2014 Omnibus Equity Incentive Plan [Member] | Maximum [Member] | |||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 36 | ||||||||||
Vesting Monthly [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 900,000 | $ 1.2 | 1.2 | $ 900,000 | 1.2 | $ 900,000 | $ 1.2 | ||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 10 months 6 days | 8 years 9 months | |||||||||
Completing Enrollment of Phase 2 OPTION 2 Clinical Trial [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 440,000 | 440,000 | 440,000 | 440,000 | |||||||
Public Announcement of Topline Data for Phase 2 OPTION 2 Clinical Trial [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 20,000 | 20,000 | 20,000 | 20,000 | |||||||
Completing Enrollment in Phase 2 Combination Trial in Europe [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 41,000 | 41,000 | 41,000 | 41,000 | |||||||
Initiating Phase 3 Trial in US [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | ||||
Public Release of Topline Data of Complete Combination Trial Results [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 140,000 | 140,000 | 140,000 | ||||||||
Signing of Definitive Term Sheet with Board Approval [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 140,000 | 140,000 | 140,000 | ||||||||
Initiating Phase 1 Trial for Product Other than MS1819 [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 40,000 | 40,000 | 40,000 | 40,000 | |||||||
Public Release of Topline Data [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 140,000 | 140,000 | 140,000 | 140,000 | |||||||
Comple Option 2 Trial Results [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 140,000 | 140,000 | 140,000 | 140,000 | |||||||
Signing Definitive Term Sheet [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 140,000 | $ 140,000 | $ 140,000 | $ 140,000 | |||||||
New Sapirstein Awards [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 90,000 | ||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 8.50 | ||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 359,000 | $ 359,000 | $ 359,000 | ||||||||
New Sapirstein Awards [Member] | Vesting Monthly [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 30,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 18 months | ||||||||||
New Sapirstein Awards [Member] | Vesting Immediately [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 20,000 | ||||||||||
New Sapirstein Awards [Member] | Milestone-based Vesting [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 40,000 | ||||||||||
New Schneiderman Awards Terms [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 25,000 | ||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 8.50 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 28,500 | ||||||||||
New Schneiderman Awards Terms [Member] | Vesting Monthly [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 17,014 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 25 months | ||||||||||
New Schneiderman Awards Terms [Member] | Vesting Immediately [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 7,986 | ||||||||||
New Schneiderman Awards 2 [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 3,500 | ||||||||||
New Schneiderman Awards 2 [Member] | Vesting Monthly [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 1,750 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 19 months | ||||||||||
New Schneiderman Awards 2 [Member] | Vesting Immediately [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 1,750 | ||||||||||
New Schneiderman Awards [Member] | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 192,000 | $ 192,000 | |||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 204,000 | ||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 8.50 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ 1,400,000 | ||||||||||
Share-based Payment Arrangement, Option [Member] | Chief Financial Officer [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 33,500 | ||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 10.30 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ 281,000 | ||||||||||
Share-based Payment Arrangement, Option [Member] | Director [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) | 46,000 | ||||||||||
Option Indexed to Issuer's Equity, Strike Price (in dollars per share) | $ 9.70 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ 210,000 | ||||||||||
Share-based Payment Arrangement, Option [Member] | The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 3 years | 3 years | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | 10 years | |||||||||
Excluding Prior Awards [Member] | The 2014 Omnibus Equity Incentive Plan [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 15,477 | ||||||||||
Service-based Vesting Options [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 23,425 | 41,614 | |||||||||
Share-based Payment Arrangement, Expense | $ 139,000 | $ 305,000 | |||||||||
Service-based Vesting Options [Member] | General and Administrative Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | 120,000 | 245,000 | |||||||||
Service-based Vesting Options [Member] | Research and Development Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | $ 20,000 | $ 60,000 | |||||||||
Performance-based Vesting Options [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 75,500 | 5,000 | |||||||||
Share-based Payment Arrangement, Expense | $ 623,000 | $ 20,000 | |||||||||
Performance-based Vesting Options [Member] | General and Administrative Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | 253,000 | ||||||||||
Performance-based Vesting Options [Member] | Research and Development Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | $ 370,000 | ||||||||||
Performance-based Vesting Options [Member] | Completing Enrollment of Phase 2 OPTION 2 Clinical Trial [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 43,750 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 427,000 | ||||||||||
Performance-based Vesting Options [Member] | Public Announcement of Topline Data for Phase 2 OPTION 2 Clinical Trial [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 21,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 148,000 | ||||||||||
Performance-based Vesting Options [Member] | Completing Enrollment in Phase 2 Combination Trial in Europe [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 750 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 8,000 | ||||||||||
Performance-based Vesting Options [Member] | Determining Initiating US Phase 1 Clinical Trial Probable [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 10,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 40,000 | ||||||||||
Service-based Vesting Options 2 [Member] | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares) | 60,008 | ||||||||||
Share-based Payment Arrangement, Expense | $ 361,000 | ||||||||||
Service-based Vesting Options 2 [Member] | General and Administrative Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | 341,000 | ||||||||||
Service-based Vesting Options 2 [Member] | Research and Development Expense [Member] | |||||||||||
Share-based Payment Arrangement, Expense | $ 20,000 |
Note 13 - Stock Options - Weigh
Note 13 - Stock Options - Weighted-average Assumptions (Details) | 9 Months Ended |
Sep. 30, 2021 | |
Contractual term (in years) (Year) | 10 years |
Volatility, minimum | 83.80% |
Volatility, maximum | 90.60% |
Risk-free interest rate, minimum | 83.90% |
Risk-free interest rate, maximum | 1.69% |
Note 13 - Stock Options - Stock
Note 13 - Stock Options - Stock Option Activity (Details) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2021USD ($)$ / sharesshares | Sep. 30, 2020USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | |
Canceled during the period (in shares) | shares | (23,500) | |||
Non-vested stock options outstanding remaining contractual life (Year) | 8 years 10 months 13 days | |||
Non-vested stock options outstanding, intrinsic value | $ | $ 0 | |||
Non-vested stock options outstanding (in shares) | shares | 167,524 | |||
Non-vested stock options outstanding, average exercise price (in dollars per share) | $ 8.44 | |||
The 2014 and 2020 Omnibus Equity Incentive Plan [Member] | ||||
Stock options outstanding (in shares) | shares | 167,750 | 167,750 | ||
Stock options outstanding, average exercise price (in dollars per share) | $ 21.70 | $ 21.70 | ||
Stock options outstanding, remaining contractual life (Year) | 6 years 6 months 7 days | 5 years 4 months 13 days | ||
Stock options outstanding, intrinsic value | $ | $ 0 | $ 0 | ||
Granted during the period (in shares) | shares | 287,001 | |||
Granted during the period, average exercise price (in dollars per share) | $ 8.90 | |||
Granted during the period remaining contractual life (Year) | 9 years 9 months 14 days | |||
Granted nonvested options during the period remaining contractual life (Year) | 10 years | |||
Canceled during the period (in shares) | shares | (23,500) | |||
Canceled during the period, average exercise price (in dollars per share) | $ 19.40 | |||
Canceled during the period remaining contractual life (Year) | 3 years 3 months 10 days | |||
Stock options outstanding (in shares) | shares | 431,251 | 167,750 | ||
Stock options outstanding, average exercise price (in dollars per share) | $ 13.80 | $ 21.70 | ||
Exercisable (in shares) | shares | 131,275 | |||
Exercisable, average exercise price (in dollars per share) | $ 22.20 | |||
Exercisable remaining contractual life (Year) | 6 years 1 month 2 days | |||
Exercisable, intrinsic value | $ | $ 0 | |||
Non-vested stock options outstanding (in shares) | shares | 88,350 | 88,350 | ||
Non-vested stock options outstanding, average exercise price (in dollars per share) | $ 13.30 | $ 13.30 | ||
Non-vested stock options outstanding remaining contractual life (Year) | 8 years 9 months | 6 years 3 months 3 days | ||
Non-vested stock options outstanding, intrinsic value | $ | $ 0 | $ 0 | ||
Granted during the period, average exercise price (in dollars per share) | $ 10 | |||
Vested during the period (in shares) | shares | (59,375) | |||
Vested during the period, average exercise price (in dollars per share) | $ 25.90 | |||
Vested during the period remaining contractual life (Year) | 6 years 10 months 17 days | |||
Canceled during the period (in shares) | shares | (16,000) | |||
Canceled during the period, average exercise price (in dollars per share) | $ 13 | |||
Canceled during the period remaining contractual life (Year) | 7 years 1 month 6 days | |||
Non-vested stock options outstanding (in shares) | shares | 299,976 | 88,350 | ||
Non-vested stock options outstanding, average exercise price (in dollars per share) | $ 9.80 | $ 13.30 | ||
The 2020 Omnibus Equity Incentive Plan [Member] | ||||
Stock options outstanding (in shares) | shares | 407,026 | |||
Stock options outstanding, average exercise price (in dollars per share) | $ 12.46 | |||
Stock options outstanding, remaining contractual life (Year) | 7 years 6 months 25 days | 7 years 11 months 8 days | ||
Stock options outstanding, intrinsic value | $ | $ 0 | $ 0 | ||
Granted during the period (in shares) | shares | 175,246 | |||
Granted during the period, average exercise price (in dollars per share) | $ 8.61 | |||
Granted during the period remaining contractual life (Year) | 10 years | |||
Canceled during the period (in shares) | shares | (134,476) | |||
Canceled during the period, average exercise price (in dollars per share) | $ 10.47 | |||
Canceled during the period remaining contractual life (Year) | 2 years 10 months 13 days | |||
Stock options outstanding (in shares) | shares | 447,796 | 407,026 | ||
Stock options outstanding, average exercise price (in dollars per share) | $ 11.55 | $ 12.46 | ||
Exercisable (in shares) | shares | 280,272 | |||
Exercisable, average exercise price (in dollars per share) | $ 13.76 | |||
Exercisable remaining contractual life (Year) | 6 years 9 months 10 days | |||
Exercisable, intrinsic value | $ | $ 0 | |||
Non-vested stock options outstanding (in shares) | shares | 274,065 | |||
Non-vested stock options outstanding, average exercise price (in dollars per share) | $ 9.90 | |||
Non-vested stock options outstanding remaining contractual life (Year) | 8 years 5 months 1 day | |||
Non-vested stock options outstanding, intrinsic value | $ | $ 0 | |||
Granted during the period, average exercise price (in dollars per share) | $ 8.61 | |||
Vested during the period (in shares) | shares | (185,870) | |||
Vested during the period, average exercise price (in dollars per share) | $ 10.38 | |||
Canceled during the period (in shares) | shares | (95,917) | |||
Canceled during the period, average exercise price (in dollars per share) | $ 0 | |||
Non-vested stock options outstanding (in shares) | shares | 274,065 | |||
Non-vested stock options outstanding, average exercise price (in dollars per share) | $ 9.90 |
Note 14 - Agreements (Details T
Note 14 - Agreements (Details Textual) - USD ($) | Feb. 24, 2021 | Jan. 08, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Feb. 23, 2021 | Dec. 31, 2020 | Dec. 30, 2020 |
Research and Development Expense, Total | $ 24,378,318 | $ 1,795,684 | $ 32,542,143 | $ 4,438,229 | |||||
Stock Issued During Period, Value, New Issues | 7,150,847 | 8,325,195 | 988,348 | ||||||
Deemed Dividends, Preferred Stock Issuances | 0 | 8,155,212 | 4,507,125 | 8,155,212 | |||||
Fair Value, Option, Changes in Fair Value, Gain (Loss) | $ 0 | $ 0 | 532,353 | $ 0 | |||||
Series C Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 33,446 | ||||||||
Series C Preferred Stock [Member] | First Wave Purchase Agreement [Member] | |||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ 7.50 | ||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 329,019 | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,290.1960 | ||||||||
Stock Issued During Period, Value, New Issues | $ 2,500,000 | ||||||||
Deemed Dividends, Preferred Stock Issuances | 230,000 | ||||||||
First Wave License Agreement [Member] | |||||||||
Asset Acquisition, Cash to be Paid in First Ten Days | $ 9,000,000 | ||||||||
Asset Acquisition, Additional Cash to be Paid | 1,250,000 | ||||||||
Asset Acquisition, Contingent Consideration, Liability, Total | $ 37,000,000 | ||||||||
Research and Development Expense, Total | 1,000,000 | ||||||||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | 3,000,000 | ||||||||
Fair Value, Option, Changes in Fair Value, Gain (Loss) | $ 500,000 | ||||||||
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value | $ 3,000,000 | ||||||||
Redeemable Noncontrolling Interest, Equity, Common, Fair Value | $ 2,500,000 | ||||||||
First Wave License Agreement [Member] | Convertible Preferred Stock [Member] | |||||||||
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 3,000,000 | ||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ 9.118 | $ 9.118 | |||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 329,019 | 329,019 |
Note 15 - Leases (Details Textu
Note 15 - Leases (Details Textual) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2021USD ($) | Sep. 30, 2020USD ($) | Jun. 01, 2021ft² | |
Operating Lease, Expense | $ | $ 79,000 | $ 55,000 | $ 186,000 | $ 129,000 | |
Office Space at 777 Yamato Road, Suite 502, Boca Raton, FL 33431 [Member] | |||||
Lessee, Operating Lease, Term of Contract (Month) | 63 months | ||||
Area of Real Estate Property (Square Foot) | ft² | 3,472 |
Note 15 - Leases - Weighted-ave
Note 15 - Leases - Weighted-average Remaining Lease Term and Weighted-average Discount Rate Under Operating Leases (Details) | Sep. 30, 2021 |
Weighted-average remaining lease term (years) (Year) | 4 years 6 months |
Weighted-average discount rate | 6.91% |
Note 15 - Leases - Maturities o
Note 15 - Leases - Maturities of Operating Lease Liabilities (Details) | Sep. 30, 2021USD ($) |
2021 | $ 57,019 |
2022 | 81,254 |
2023 | 83,691 |
2024 | 86,202 |
2025 | 88,788 |
Thereafter | 60,593 |
Total lease payments | 457,547 |
Less imputed interest | (67,064) |
Present value of lease liabilities | $ 390,483 |
Note 16 - Income Taxes (Details
Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | |
Unrecognized Tax Benefits, Ending Balance | $ 0 | $ 0 |
Note 17 - Net Loss Per Common_2
Note 17 - Net Loss Per Common Share (Details Textual) - shares | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Common Stock and Series B Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 721,364 | 2,931,440 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 5,509,675 | 736,118 |
Restricted Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 11,200 | |
Restricted Stock and Restricted Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 27,500 | 38,700 |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 448,296 | 227,250 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 2,931,440 | |
Outstanding Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 2,520,016 | |
Uneared and Unissued Restricted Stock and RSU 2 [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 38,700 | |
Outstanding Employee Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 431,250 |
Note 18 - Employee Benefit Pl_2
Note 18 - Employee Benefit Plans (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage | 6.00% | |||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 26,000 | $ 40,000 | $ 81,000 | $ 62,000 |
Minimum [Member] | ||||
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 1.00% | |||
Maximum [Member] | ||||
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 100.00% |
Note 19 - Subsequent Events (De
Note 19 - Subsequent Events (Details Textual) - USD ($) | Nov. 15, 2021 | Oct. 29, 2021 | Oct. 04, 2021 | Nov. 14, 2021 | Aug. 31, 2022 | Aug. 30, 2022 | Jul. 31, 2023 |
Fortis Advisors Complaint [Member] | Forecast [Member] | |||||||
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment | $ 500,000 | $ 500,000 | $ 1,000,000 | ||||
Subsequent Event [Member] | Fortis Advisors Complaint [Member] | |||||||
Loss Contingency, Damages Sought, Value | $ 8,000,000 | ||||||
Litigation Settlement, Amount Awarded to Other Party Immediately | $ 2,000,000 | ||||||
Litigation Settlement, Amount Awarded to Other Party | $ 17,000,000 | ||||||
Subsequent Event [Member] | Conversion of Series B Preferred Stock to Common Stock [Member] | |||||||
Conversion of Stock, Shares Converted (in shares) | 13.80 | ||||||
Conversion of Stock, Amount Converted | $ 113,900 | ||||||
Conversion of Stock, Shares Issued (in shares) | 33,500 | ||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ 3.40 | ||||||
Subsequent Event [Member] | Milestone For Clinical Development [Member] | |||||||
Payment for Contingent Consideration Liability, Operating Activities | $ 2,000,000 |